US20170311824A1 - Non-invasively monitoring blood parameters - Google Patents
Non-invasively monitoring blood parameters Download PDFInfo
- Publication number
- US20170311824A1 US20170311824A1 US15/649,908 US201715649908A US2017311824A1 US 20170311824 A1 US20170311824 A1 US 20170311824A1 US 201715649908 A US201715649908 A US 201715649908A US 2017311824 A1 US2017311824 A1 US 2017311824A1
- Authority
- US
- United States
- Prior art keywords
- pulse waveform
- waveform signal
- signal
- blood
- photodetector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012544 monitoring process Methods 0.000 title claims abstract description 34
- 210000004369 blood Anatomy 0.000 title claims description 51
- 239000008280 blood Substances 0.000 title claims description 51
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000004044 response Effects 0.000 claims abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 28
- 229910052760 oxygen Inorganic materials 0.000 claims description 28
- 239000001301 oxygen Substances 0.000 claims description 28
- 230000010412 perfusion Effects 0.000 claims description 15
- 238000005070 sampling Methods 0.000 claims description 10
- 239000000853 adhesive Substances 0.000 claims description 7
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 210000001061 forehead Anatomy 0.000 claims description 6
- 238000002496 oximetry Methods 0.000 claims 2
- 230000001960 triggered effect Effects 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 abstract description 21
- 238000002834 transmittance Methods 0.000 abstract description 14
- 210000003414 extremity Anatomy 0.000 description 75
- 210000003128 head Anatomy 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 37
- 230000003287 optical effect Effects 0.000 description 32
- 230000036772 blood pressure Effects 0.000 description 30
- 230000010355 oscillation Effects 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 17
- 230000036541 health Effects 0.000 description 16
- 230000000712 assembly Effects 0.000 description 14
- 238000000429 assembly Methods 0.000 description 14
- 102000001554 Hemoglobins Human genes 0.000 description 13
- 108010054147 Hemoglobins Proteins 0.000 description 13
- 230000035488 systolic blood pressure Effects 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 238000005086 pumping Methods 0.000 description 10
- 230000029058 respiratory gaseous exchange Effects 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 230000004872 arterial blood pressure Effects 0.000 description 8
- 230000035487 diastolic blood pressure Effects 0.000 description 8
- 230000005540 biological transmission Effects 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000008602 contraction Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000001020 rhythmical effect Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 3
- 238000009530 blood pressure measurement Methods 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000001765 aortic valve Anatomy 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 210000000624 ear auricle Anatomy 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000009528 vital sign measurement Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 229920001821 foam rubber Polymers 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000718 qrs complex Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/024—Measuring pulse rate or heart rate
- A61B5/02416—Measuring pulse rate or heart rate using photoplethysmograph signals, e.g. generated by infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/02108—Measuring pressure in heart or blood vessels from analysis of pulse wave characteristics
- A61B5/02125—Measuring pressure in heart or blood vessels from analysis of pulse wave characteristics of pulse wave propagation time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14552—Details of sensors specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6814—Head
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6825—Hand
- A61B5/6826—Finger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/683—Means for maintaining contact with the body
- A61B5/6838—Clamps or clips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
- A61B2560/04—Constructional details of apparatus
- A61B2560/0406—Constructional details of apparatus specially shaped apparatus housings
- A61B2560/0412—Low-profile patch shaped housings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6824—Arm or wrist
Definitions
- the present invention relates to medical devices and, more particularly, to apparatuses and methods for non-invasively monitoring vital sign parameters of a biological entity, such as a neonate.
- a basic requirement in determining the health of a human adult or neonate is to measure certain vital sign parameters, such as blood pressure, pulse rate, blood oxygen saturation, and respiratory rate.
- measuring blood pressure in a human adult is typically accomplished using either an oscillometric-based method or an auscultatory method, both of which traditionally involve the application of an inflatable blood pressure cuff around the arm of the subject. While oscillometric-based and auscultatory methods are easily implemented with a human adult, these methods are not well suited for subjects such as neonates due to their diminutive size and inability to comprehend and cooperate with the procedure.
- the apparatuses and methods should be easily implemented and obtain accurate results, as well as be carried out in a near-continuous manner so as to allow for monitoring without disturbing the subject. Also, the apparatuses and methods should be employed such that any biological entity, regardless of size, may be monitored.
- the present invention provides apparatuses for monitoring vital sign parameters of a biological entity.
- the apparatuses include at least one light source for transmitting light through the biological entity and at least one photodetector for receiving light transmitted through the biological member. At least one light source and at least one photodetector are configured to be positioned proximate the biological entity in a manner that does not significantly impede blood flow through the biological entity.
- a signal is generated in response to the transmittance or reflectance of light through the biological entity. The signal corresponds to at least one characteristic of the generally unimpeded blood flow through the biological member.
- the apparatuses also include a control system configured to analyze the signal to determine blood pressure, oxygen saturation, pulse rate, perfusion index, cardiac index, vascular elasticity, and respiration, among other blood parameters, of the biological entity.
- the present invention also provides methods for monitoring vital sign parameters in a biological entity.
- the method includes positioning at least one sensor assembly proximate the biological entity.
- a signal is generated by at least one sensor assembly that corresponds to at least one characteristic of the blood flow through the biological entity.
- the signal is analyzed to determine blood pressure, oxygen saturation, pulse rate, perfusion index, cardiac index, vascular elasticity, and respiration, among other blood parameters, of the biological entity.
- FIG. 1A depicts, from a first perspective, a trans-illuminating cuff according to an embodiment of the invention
- FIG. 1B is a cross-sectional view of the trans-illuminating cuff of FIG. 1A ;
- FIG. 2 is a view of the trans-illuminating cuff of FIG. 1A from a second perspective;
- FIG. 3 is a depiction of the trans-illuminating cuff of FIG. 1A from a third perspective;
- FIG. 4 is a perspective view of a trans-illuminating cuff according to another embodiment of the invention.
- FIGS. 5A and 5B depict two possible optical paths that may be established through a biological member
- FIG. 6A is a perspective view of the trans-illuminating cuff of FIG. 1A applied to the arm of a neonate;
- FIG. 6B is a perspective view of the trans-illuminating cuff of FIG. 1A applied to the finger of an adult;
- FIG. 7 depicts, from a first perspective, a trans-illuminating patch according to another embodiment of the invention.
- FIG. 8 is a view of the trans-illuminating patch of FIG. 7 from a second perspective
- FIG. 9 is a front elevational view of the trans-illuminating patch of FIG. 7 applied to the head and neck of an adult;
- FIG. 10 is a perspective view of a trans-illuminating clip according to another embodiment of the invention.
- FIG. 11 is a block diagram of a vital sign parameter control system incorporating the trans-illuminating cuff of FIG. 1A and the trans-illuminating patch of FIG. 7 ;
- FIG. 12A are exemplary pulse waveform signals obtained from the use of the trans-illuminating cuff of FIG. 1A and the-trans-illuminating patch of FIG. 7 with a biological member, such as the arm or head of a neonate;
- FIGS. 12B-12D are exemplary pulse waveform signals of FIG. 12A that have been positioned within an analysis envelope;
- FIGS. 13A and 13B are further exemplary pulse waveform signals illustrating optical oscillometric blood pressure measurements with a vital sign monitor
- FIG. 14 is a graph that illustrates the spectral characteristics of hemoglobin (Hb) and oxygenated hemoglobin (HbO2);
- FIG. 15 illustrates the presence of respiratory variations in the graphs of transmittance of light of first and second wavelengths
- FIGS. 16A and 16B is an exemplary pulse waveform signal that has been labeled to define areas of interest that are related to the pumping action of a heart;
- FIG. 17 is an enlarged exemplary pulse waveform signal of FIG. 12A to illustrate transition points of the signal.
- FIGS. 18A and 18B are exemplary electrocardiogram signals and an exemplary pulse waveform signals shown for comparison purposes.
- FIG. 1A Illustrated in FIG. 1A is one side of a member trans-illuminating cuff 100 for monitoring certain vital sign parameters of a biological entity.
- a particular biological entity that is discussed in the several embodiments is a newborn, neonate, or infant (collectively referred to as “neonate” for the remainder of the application and understood to represent not only a person in their early stages of life, but any person of relatively diminutive size, such as an infant, regardless of age).
- neonate a newborn, neonate, or infant
- these several embodiments in use with a neonate it must be understood that these embodiments may also be used to monitor the vital signs of other biological entities such as an adult person or animals (e.g., canines and primates).
- cuff 100 includes a flexible support member 122 that can be readily wrapped or applied around an arm, leg, finger or other appendage (collectively referred to as a “limb” for the remainder of the application) of a biological entity.
- limb for the remainder of the application
- Incorporated within or mounted upon one side of cuff 100 is at least one light source 132 and at least one photodetector 134 positioned to diametrically oppose light source 132 when cuff 100 is applied over a limb of a neonate.
- One suitable type of light source for use in cuff 100 is a light emitting diode (LED), such as the type L660/805/975-40D00, available from Epitex, Kyoto, Japan, and a suitable photodetector is a photoresistor or photodiode, such as the QSD723 photoresistor available from QT Optoelectronics.
- LED light emitting diode
- a suitable photodetector is a photoresistor or photodiode, such as the QSD723 photoresistor available from QT Optoelectronics.
- other light sources and photodetectors for generating and receiving one of more frequencies of light may also be used in cuff 100 without departing from the spirit and scope of the invention.
- cuff 100 includes two light sources 132 a and 132 b that are spaced along the interior side of cuff 100 so as to oppose photodetector 134 when cuff 100 is applied over a limb 200 (see, e.g., FIG. 5A ).
- This dual light source configuration provides for increased transmission of light through the tissue bed and around a bone 210 of limb 200 .
- light source 132 and photodetector 134 may be positioned side-by-side to allow for the monitoring of blood parameters based not on light transmitted directly from the light source 132 to the photodetector 134 , but instead on light transmitted into the tissue of the limb 200 by light source 132 and subsequently reflected back to photodetector 134 (see, e.g., FIG. 5B ).
- cuff 100 also includes an attachment device 138 for securing cuff 100 to limb 200 of a neonate.
- attachment device 138 includes a cinch-loop 140 attached to a first end 142 of the flexible support member 122 through which a second end 144 extends when cuff 100 is applied to the limb of a neonate.
- hook-and-loop style fastener components 146 a and 146 b, such as Velcro are applied to the second, or exterior, side of flexible support member 122 .
- fastener components 146 a and 146 b may be used to secure the cuff 100 in its wrapped position without significantly impeding the flow of blood through the limb (see, e.g., FIGS. 6A and 6B ).
- cuff 100 may lack a cinch-loop 140 , relying entirely on hook-and-loop style fastener components 146 a and 146 b to secure cuff 100 .
- further embodiments may forgo the hook-and-loop style fastener components 146 a and 146 b in favor of other attachment means, such as, for instance, adhesives, reusable or otherwise, and other types of variable tension fastening systems.
- cuff 100 may optionally include one or more inflatable bladders 124 that are either incorporated into cuff 100 or mounted to an interior side of cuff 100 .
- bladder 124 may be inflated to a relatively low pressure level that would aid in securing cuff 100 in position while not significantly impeding the flow of blood through limb 200 .
- bladder 124 mounts to an interior side of cuff 100 over light source 132 and photodetector 134 .
- bladder 124 may be fashioned from a material, such as polyurethane, which is optically transparent to the wavelength of light emitted by light source 132 and to which photodetector 134 is sensitive.
- cuff 100 may incorporate a bladder 124 in such a manner that when bladder 124 is inflated, light source 132 and photodetector 134 remain in contact with or proximal to limb 200 . This can be accomplished, for example, by configuring cuff 100 so that light source 132 and photodetector 134 are mounted not upon flexible support member 122 , but upon bladder 124 .
- flexible support member 122 may include a generally cylindrical sleeve (not illustrated) that may be slipped around the limb 200 of a neonate.
- the generally cylindrical sleeve may possess elastic characteristics that allow it to stretch and contract as a limb 200 is inserted into the sleeve. The contractile forces generated by the sleeve as it is slipped around a limb 200 also serve to secure the placement of the sleeve without significantly impeding blood flow through the limb.
- flexible support member 122 may include a generally cylindrical sleeve that does not have elastic characteristics. Instead, at least one bladder 124 may be incorporated into the sleeve or mounted upon the interior surface of the sleeve. Once sleeve is slipped around the limb 200 of a neonate, bladder 124 may be inflated with sufficient pressure to secure the sleeve around the limb without significantly impeding blood flow. If desired, the bladder may also be inflated to a pressure exceeding the systolic blood pressure of the subject, thereby substantially obstructing the flow of blood through limb 200 .
- a trans-illuminating cuff 300 that includes a rigid or semi-rigid housing 310 , such as a plastic tube, into which limb 200 of the neonate can be inserted.
- a rigid or semi-rigid housing 310 such as a plastic tube
- at least one light source 332 and at least one photodetector 334 are incorporated into or mounted upon housing 310 in such a manner that, upon insertion of limb 200 , light source 332 may transmit light through the tissue of limb 200 , with the transmitted light subsequently being received by photodetector 334 .
- a resilient sleeve or layer of material 320 may be incorporated with, or mounted onto, the interior surface of housing 310 .
- Resilient layer 320 may include, for example, foam rubber and other materials that readily compress upon being pressed against limb 200 .
- a fixed diameter housing 310 may accommodate various limb sizes, the resilient layer 320 compressing and expanding as needed to generally conform to the shape of limb 200 .
- resilient layer 320 may be configured so that it does not obstruct the transmission of light from light source 332 into the tissue of limb 200 , nor interfere with the reception of light by photodetector 334 .
- resilient layer 320 This can be accomplished through selective placement of resilient layer 320 or, alternatively, by making resilient layer 320 out of a material that is optically transparent to the wavelengths) of light transmitted by light source 332 and received by photodetector 334 .
- light source 332 and photodetector 334 may be positioned on resilient layer 320 instead of housing 310 .
- resilient layer 320 aids in positioning the light source 332 and photodetector 334 in close proximity to limb 200 as layer 320 expands and contracts in response to the presence of limb 200 .
- housing 310 of cuff 300 may be configured so that resilient layer 320 is supplemented or replaced by at least one bladder (see, e.g., bladder 124 ) that are selectively inflatable to a pressure level sufficient to hold housing 310 in place on limb 200 without significantly impeding the flow of blood through limb 200 .
- the bladder(s) may also be selectively inflated to a pressure exceeding the systolic blood pressure of the neonate, thereby substantially obstructing the flow of blood through limb 200 .
- a trans-illuminating patch 400 is provided. Similar to previous embodiments, at least one light source 432 and at least one photodetector 434 are incorporated into or mounted upon patch 400 . Unlike the previous embodiments, patch 400 may be placed on any location or position of the neonate's body and used to monitor the vital sign parameters. Limb 200 may be used for placement, but is not required. Patch 400 may be positioned on the neonate's head, chest, neck, thigh, or other suitable location to monitor vital sign parameters (see e.g., FIG. 9 , patch 400 is positioned on the head and neck of an adult person). Patch 400 may be attached to the particular area of the body with adhesives, reusable or otherwise, or some other attachment device such as a bandage, headband, or the like.
- Patch 400 may be positioned on the neonate in relatively flat locations rather than encircling limb 200 like cuffs 100 , 300 . Therefore, light source 432 and photodetector 434 may be positioned side-by-side to allow for monitoring of vital sign parameters based not on light transmitted directly from the light source 432 to photodetector 434 , but instead on light transmitted into the tissue of the neonate's body by light source 432 and subsequently reflected back to photodetector 434 (see, e.g., FIG. 5B ).
- patch 400 may also include one or more inflatable bladders (see, e.g., bladder 124 ) that are incorporated into patch 400 .
- the bladders may be mounted to patch 400 such that the bladders may be between the neonate and the patch 400 .
- the bladders may be fashioned from a material, such as polyurethane, which is optically transparent to the wavelength of light emitted by light sources 432 and to which photodetector 434 is sensitive.
- the bladders may be selectively inflated to a pressure exceeding the systolic blood pressure of the neonate, thereby substantially obstructing the flow of blood through that particular area of the neonate's body.
- a trans-illuminating clip 500 is provided. Similar to previous embodiments, at least one light source 532 and at least one photodetector 534 are incorporated into or mounted upon clip 500 .
- Clip 500 may be secured to smaller portions of the body such as earlobes, fingers, toes, and the like, and used to monitor the vital sign parameters. (see e.g., FIG. 9 , clip 500 is positioned on the earlobe of an adult person).
- Clip 500 includes an attachment device 538 that includes a biasing member 540 such as a spring, resilient rubber, or the like, to ensure that light source 532 and photodetector 534 remain proximate the tissue of the neonate.
- control system 600 includes a processor 605 that controls, among other things, operation of light sources (e.g., 132 , 432 ) and photodetectors (e.g., 134 , 434 ) in a sensor assembly (e.g. cuff 100 , patch 400 ).
- a sensor assembly e.g. cuff 100 , patch 400 .
- the sensor assembly employing light sources and photodetectors is the preferred means of generating a signal relating to vital sign parameters, it must be understood that equivalent means for generating signals relating to vital sign parameters may be employed such as ultrasound or the like.
- control system 600 is discussed controlling two sensor assemblies, it should be understood that control system 600 may control multiple channels so that multiple sensor assemblies, that are positioned on a neonate, may be used in monitoring vital sign parameters.
- the microprocessor energizes the light sources continually.
- photodetectors convert the light transmitted through the tissue in limb 200 or reflected in head 450 (or other part of the body such as the neck, chest, or thigh) into a corresponding electronic signal.
- This electronic signal is subsequently supplied to processor 605 for analysis after being optionally passed through amplifiers 610 a and 610 b.
- the amplified photodetector output signal is converted to digital form in the microprocessor itself if the microprocessor has an internal A/D converter, or in a separate A/D converter provided between the amplifier and the microprocessor.
- Results of the analysis may then be directed to a variety of output devices, such as, for example, a display screen 620 .
- processor 605 is depicted as being separate from the sensor assemblies. However, in an alternative embodiment, control system 600 may be more integrated into the sensor assemblies, with one or more of the components, including processor 605 , being incorporated into the sensor assemblies.
- the sensor assemblies may also communicate with pumps 630 a, 630 b if one or more inflatable bladders are included in the sensor assemblies. Inflation and deflation of the bladders may be readily controlled by pumps 630 a, 630 b.
- pumps 630 a, 630 b are controlled by processor 605 and convey air into the inflatable bladders through inflation tubes 635 a and 635 b.
- Pressure transducers 640 a and 640 b may also be incorporated into control system 600 for monitoring the pressure in inflation tubes 635 a and 635 b and the bladders, and conveying signals indicative of such pressure back to the processor 605 . Suitable transducers are available from Cobe Labs, Littleton, Colo.
- a first sensor assembly e.g., cuff 100
- a second sensor assembly e.g., patch 400
- control system 600 activates the sensor assemblies by operating or energizing light sources (e.g., 132 , 432 ) and photodetectors (e.g., 134 , 434 ).
- the light sources begin to transmit light of a first wavelength or frequency.
- This transmitted light representing an optical signal
- This transmitted light passes through the skin and into the tissue of limb 200 (see, e.g., FIG. 5A ) and passes through the skin and is reflected off the skull in head 450 (see, e.g., FIG. 5B ).
- the optical signal continues to travel through the tissue making up limb 200 and head 450 , including, for example, various types of skin tissue, muscle, and blood vessels.
- portions of the signal are deflected or absorbed.
- the remainder of the optical signal that makes it through the tissue of limb 200 is received by the photodetector.
- the remainder of the optical signal that is reflected through the tissue of head 450 is received by the photodetector.
- the photodetectors subsequently convert the optical signals into electric signals to be sent to control system 600 .
- this electric signal produced by the photodetectors represents the transmittance (T) of the optical signal through the tissue of limb 200 and the reflectance (R) through the tissue of head 450 at that moment in time.
- This transmittance (T) or reflectance (R) of the optical signal is not constant, but continuously fluctuates due to ongoing changes occurring in the tissue of limb 200 and head 450 , including without limitation, changes in blood flow.
- blood is distributed throughout limb 200 and head 450 by a variety of blood vessels, including, for example, arteries and arterioles.
- the rate and volume of blood flow through these vessels is largely dependent on blood pressure levels, which in turn are dependent on the pumping action of the heart as well as the blood vessels themselves, some of which constrict or dilate depending on the current biological state of the subject. Accordingly, the transmittance (T) of the optical signals through the tissue of limb 200 and reflectance (R) of the optical signals through the tissue of the head 450 are dependent on volumetric changes in blood flow, which, in turn, are dependent on blood pressure levels.
- Pulse waveform signal 700 a is obtained after securing the first sensor assembly around limb 200 and energizing the light source and the photodetector.
- a similar pulse waveform 700 b is obtained after securing the second sensor assembly to head 450 and energizing the light source and the photodetector.
- the rhythmic pattern of fluctuations or oscillations within pulse waveform signals 700 a, 700 b represent changes in the volumetric flow of blood through limb 200 or head 450 primarily due to the pumping or “beating” action of the human heart.
- pulse waveform signals 700 a, 700 b permit the determination of certain blood parameters that influence the flow of blood, such as, for example, mean arterial blood pressure, diastolic blood pressure and systolic blood pressure. This determination is possible due to the relationships, as discussed above, between transmittance (T) of the optical signal and between reflectance (R) of the optical signal, volumetric changes in blood flow, and blood pressure levels.
- analysis of pulse waveform signals 700 a, 700 b includes the application of one or more algorithms that manipulate the data of pulse waveform signals 700 a, 700 b in accordance with one or more predefined relationships that exist between transmittance (T) and reflectance (R) of the optical signal, blood flow and blood pressure levels. This is further discussed below.
- the microprocessor may be suitably programmed to generate an envelope 702 from the pulse waveform signal.
- Envelope 702 is comprised of a lower band 704 and upper band 706 that may be positioned around subsequent pulse waveform signals.
- Envelope 702 may be used to further aid health care professionals in the near continuous monitoring of a neonate's vital sign parameters and for diagnostic analysis.
- Microprocessor 605 may generate envelope 702 from pulse waveform signal 700 a by using a signal sampling technique that is known in the art of signal processing.
- the microprocessor may be programmed to “sample” the pulse waveform signal periodically. Sampling the pulse waveform signal produces a second signal that may be similar to the original pulse waveform signal. The number of samples taken and the time period between samples will determine how closely the sampled signal resembles the original pulse waveform signal taken from the cuff, patch or other like device.
- the microprocessor may be programmed such that lower band 704 and upper band 706 may be developed from the sampled signal, as determined by a healthcare professional, by adjusting the signal gain to produce envelope 702 .
- FIG. 120 illustrates envelope 702 that is a set of simple limit bars (lower band 704 and upper band 706 ) that are based on a sampled electrical signal from the sensor assembly.
- microprocessor samples the pulse waveform signal at only a few points to identify the peak value of the pulse waveform signal. The microprocessor then sets the lower and upper bands of the envelope based upon the peak value or as directed by a healthcare professional.
- envelope 702 more closely resembles the pulse waveform signal that was generated by the microprocessor from the electrical signal received from the sensor assembly.
- the envelope in FIG. 12C is based on more frequent sampling of the pulse waveform signal than the envelope in FIG. 12B .
- the envelope in FIG. 12D is based on an even greater frequency of sampling of the pulse waveform signal then the envelope in FIG. 12C so that the lower and upper bands more closely resemble the actual pulse waveform signal.
- the sampling period of the microprocessor may be adjusted to be used in the manner determined by the health care professional.
- the greater the frequency of the sampling period the greater the number of sampling points generated, and the more the envelope will resemble the actual electrical signal from the sensor assembly. In this manner the health care professional will have greater precision when employing the use of an envelope in a diagnostic analysis or a near continuous monitor mode.
- envelope 702 may be employed for a number of continuous monitoring and diagnostic analysis techniques. For example, an audible alert may be incorporated into control system 600 such that during continuous monitoring of a neonate with sensor assemblies, an alarm may be sounded if the incoming electrical signal crosses either lower band 704 or upper band 706 indicating a unwanted change in vital sign parameters.
- pulse waveform signal 700 a may be analyzed through a process of comparing signal 700 a to a number of previously established pulse waveform signals that have already been associated with one or more known vital sign measurements.
- the present analysis method involves the creation of a database of reference envelopes based on previous pulse waveform signals and corresponding blood flow characteristics associated with the reference signals. Each individual envelope characteristic in the database or, alternatively, a combination of two or more envelope characteristics, is then associated with one or more vital sign measurements, such as, for example, blood pressure respiration, and heart rate.
- a pulse waveform signal 700 a undergoing analysis is evaluated for one or more identifiable and defining characteristics.
- These defining characteristics in the evaluated pulse waveform signal 700 a are compared to the established envelope characteristics maintained in the database. If this comparison meets certain predetermined criteria between the characteristics of the pulse waveform signal 700 a being analyzed and the specific reference characteristics stored in the database, it can be assumed that the blood parameters associated with pulse waveform signal 700 a are the same as the known blood parameters associated with the selected reference envelopes stored in the database. The known blood parameters corresponding to the monitored waveform signal 700 a may then be presented to the healthcare provider, such as on display 620 .
- the envelopes developed from the pulse waveform signals may be generated and stored in databases for an entire population.
- a generic database of envelopes may be developed that may be based on age, gender, size, or any number of attributes. By employing the use of these databases, health care professionals may be able to establish a base line reading for those people who have not had a medical physical in quite some time. Rather than taking several months or years to establish a baseline, a generic pulse waveform envelope baseline can be drawn from the database based on parameters such as size, age, and gender, and the person's pulse waveform signal monitored against established envelopes. While, every person will still require an individual assessment, irregularities may be identified in advance with the use of the generic database of envelopes that closely correspond to a particular person's size, age, gender, etc.
- an individual database of envelopes may be developed for future diagnostic analysis.
- One example may involve a person who visits his health care professional for regular physicals. Each time the person returns his yearly physical, the healthcare professional can access his previous envelopes to be used in comparison purposes with the new pulse waveform signal that is presently being generated. The healthcare professional may be alerted to potential physiological problems if the new signal passes outside the envelope indicating a change in the person's vital sign parameters.
- a person may find himself in an accident where he is unconscious and cannot communicate with onsite health care professionals.
- Identification information about the victim can be entered into a computer and the onsite professionals can access the victim's database of pulse waveform signal envelopes to identify any of the victim's vital sign parameter abnormalities that may require attention prior to treating the victim. In this manner, people may receive a relatively quick and accurate diagnosis, which in turn leads to quick and more importantly the correct form of treatment.
- Physiological markers that may be monitored and measured by these embodiments may include, but are not limited to, glucose levels, lactate, C-reactive protein, cytokines, white blood cell counts, and gene or protein expression in-vivo. These biological markers not only provide insight into the health status, but also address pre-symptomatic activity due to infection, chemical or biological agent exposure.
- Microprocessor 605 may also compare pulse waveform signal 700 a produced from the first sensor assembly positioned around limb 200 (see e.g., FIGS. 6A and 6B ), with pulse waveform signal 700 b produced from the second sensor assembly positioned on head 450 (see e.g., FIG. 9 ).
- a database of envelope signals may be created for comparison purposes.
- the health care provider may monitor these waveforms-taken from different areas of the subject to diagnosis possible internal biological problems that may be found between the monitoring devices.
- the two separate sensor assemblies may be used in conjunction with one another for vital sign comparison purposes and analysis of the neonate.
- the sensor assembly may also be configured to actively measure blood pressure of a subject through an oscillometric-based method.
- the sensor assembly may include at least one inflatable bladder selectively operable to occlude blood flow in limb 200 or head 450 upon inflation to a sufficiently high enough pressure.
- FIGS. 13A and 13B depicts a pulse waveform signal 710 along with a graph 720 of corresponding sensor assembly pressure.
- a pulse waveform signal 710 is obtained by applying the sensor assembly around limb 200 or to head 450 of the subject and then subsequently energizing the light source to transmit an optical signal through the tissue of the limb or the head to the photodetector.
- the sensor assembly will generate a first pulse waveform signal 710 a that is similar in nature to the pulse waveform signals 700 a, 700 b obtained in the previously discussed embodiment of the invention.
- pump 630 a, 630 b activates, thereby increasing the pressure in the bladders, as illustrated in FIGS. 13A and 13B by graph segment 722 .
- sensor assembly begins to constrict limb 200 or head 450 . This constriction causes at least a partial pinching of the blood vessels running through the limb or the head, which, in turn, impedes blood flow through the blood vessels.
- the pulses or oscillations in the pulse waveform signal 710 b first increase in amplitude, reach a maximum, and then decrease in amplitude.
- the transition period DE in bladder pressure results in amplified oscillations or spikes in the pulse waveform signal (see, e.g., segment 710 d ).
- the oscillations in the pulse waveform signal return to a substantially uniform level.
- the pulse waveform signal exhibits transient increases in the amplitude of the oscillations occurring in the signal (see, e.g., segments 710 b and 710 d ).
- the microprocessor is also sampling the incoming signal so that an envelope 715 may be generated based upon the transient signal.
- the positive peak of the envelope is at a point where the pulse amplitude reaches a maximum, identified as mean arterial blood pressure (A m ) in FIGS. 13A and 13B .
- the maximum amplitude of the pulse is also a point where the bladder pressure is substantially equal to mean arterial blood pressure.
- waveform signal segments 710 b and 710 d that correspond to diastolic blood pressure and systolic blood pressure.
- the determination of the oscillation amplitudes at these points allows for the determination of diastolic and systolic blood pressure.
- Empirical studies indicate that these oscillation amplitudes, identified as A d for diastolic pressure and A s for systolic pressure, are related to the oscillation amplitude A m , which corresponds to mean arterial blood pressure.
- diastolic blood pressure can be identified by first determining the relationship between A d and A m , which is a fixed constant, and then determining oscillation amplitude A m , which is readily identifiable since, by definition, it is the oscillation of maximum amplitude.
- Systolic blood pressure can be identified in a similar manner.
- X and Y are constants that are empirically determined based on certain characteristics of the subject, such as shape.
- a m is a fixed constant value while the relationship of A s /A m may determined by a linear algorithm.
- the steady state signal occurring after the deflation of the bladder will have the characteristics of the calculated blood pressure.
- the steady state signal (e.g. graph segment 710 e ) generated by the sensor assembly after the measurement of mean arterial pressure and deflation of the bladder, may be monitored in a near-continuous manner.
- the steady state signal generated after the deflation of the bladder is a signature of the measured mean arterial pressure and the calculated blood pressure.
- an envelope may be positioned around waveform signal 710 e and then monitored for one or more predetermined signal characteristics, such as any substantial deviations or fluctuations occurring in the electrical signal that may cross either the lower or upper limit bands of the envelope and indicated an abnormal condition in the neonate.
- Provided pulse waveform signal 710 e remains in a steady state or near steady state condition, it may be assumed that the previously measured blood pressures levels correlating to the waveform signals 710 e have not substantially changed. If at any time the generated signal from the sensor assembly passes outside of the envelope, control system 600 may be programmed to trigger an alarm to notify health care professionals of the irregularity and/or perform a new blood pressure measurement and calculation as described above.
- an actual blood pressure measurement involving inflation of the bladder and subsequent analysis of the pulse waveform signal 710 occurs only when changes in the waveform signal 710 e indicate probable changes in blood pressure.
- continuous monitoring of blood pressure can be maintained without having the intrusive inflating and deflating of the bladder that may disturb the subject.
- the sensor assembly may also provide near-continuous monitoring of the pulse or heart rate of the subject. This is accomplished in a manner similar to that previously discussed for providing near-continuous monitoring of blood pressures. Specifically, the sensor assembly is applied to a limb of the subject. If the sensor assembly includes one or more bladders, they should be deflated so as to not constrict the limb, and, consequently, impede blood flow. The light source and the photodetector are energized, generating a pulse waveform signal such as that illustrated in FIG. 12 . A similar waveform signal may be generated by a sensor assembly located elsewhere on the subject such as the head.
- the pulse waveform signals 700 a, 700 b are indicative of the volumetric changes occurring in the flow of blood through the limb or head.
- a typical pulse waveform signal 700 will be characterized by a rhythmic pattern of fluctuations or oscillations in the signal. These oscillations represent near-continuous changes in the volumetric blood flow due to the pumping or “beating” action of the heart or cardiac muscle. Consequently, heart rate can be monitored by analyzing the waveform signal and determining the number of oscillations that occur within a predetermined period of time.
- HbO2 hemoglobin
- Hb+HbO2 oxygenated hemoglobin
- control system 600 may be configured to function as a pulse oximeter.
- the sensor assembly may be configured to generate light of two different wavelengths, such as, for example, 650 nanometers (nm) and 805 nm.
- 650 nanometers nm
- 805 nm nm
- hemoglobin (Hb) offers negligible transmission of light having a wavelength of 650 nm
- oxygenated hemoglobin HbO2
- light having a wavelength of 805 nm transmits equally well though both hemoglobin (Hb) and oxygenated hemoglobin (HbO2).
- the transmission of light at 650 nm indicates a density of oxygenated hemoglobin (HbO2)
- the transmission of light at 805 nm indicates a density of total hemoglobin (Hb+HbO2).
- control unit 600 may be configured to alternately energize the two light sources of the sensor assembly in rapid succession, e.g., energizing the light sources at 200 pulses per second. In this manner, high-intensity, short duration pulses of first and second wavelengths of light are alternately transmitted through the tissue of limb 200 or head 450 . After passing through the tissue of limb 200 or reflecting through the tissue of head 450 , the alternating streams of light are received by the photodetectors, which, according to this embodiment, is a broadband photodetector capable of detecting both wavelengths. Alternatively, two separate narrow band photodetectors can be used with the sensor assembly, each photodetector capable of detecting light of one wavelength but not light of the other wavelength.
- the photodetectors convert the two alternating optical signals of different wavelengths into an electric signal representing the transmittance of two wavelengths.
- Processor 605 analyzes the signal and determines the optical density for each of the two wavelengths.
- the ratio of first wavelength to second wavelength optical density is subsequently calculated and scaled to provide an output value corresponding to the percentage of oxygen saturation.
- the output value generated from the ratio of optical densities can be compared to an appropriate calibration curve programmed into processor 605 , such as, for example, in the form of a lookup table.
- the calibration curve relates optical density to a suspension, such as blood, and is derived from a variation of Beer's law that relates optical density to the concentration of a dissolved substance.
- the senor assembly includes at least one inflatable bladder.
- the bladder may be inflated to a sufficiently high enough pressure so that it constricts the limb or head and drives or squeezes substantially all the blood out of the vessels that run within the portion of the limb or head located in the cuff or beneath the patch. The constriction of the limb or head ensures a lack of blood within the optical path established between the light source and the photodetector. An optical signal passed through these bloodless regions of the limb and head can then be assigned a 100% transmission value.
- the photodetectors can be synchronously energized with the light sources. This feature ensures that the photodetectors are turned on only when a light source is energized, and minimizes the amount of power drawn by the system, as well as the amount of heat generated by the light sources and photodetectors.
- the present invention may also be configured to monitor the respiration rate of a neonate.
- blood oxygen saturation levels vary subtly with the breathing process, which includes the inspiration of oxygen and expiration of waste gases such as carbon dioxide.
- the sensor assembly possesses short enough response times in its measuring capabilities to detect the subtle rhythmic changes that occur in blood oxygen saturation levels due to the breathing process.
- FIG. 15 depicts an analog recording of the transmittance of the first and second wavelengths of light, such as 650 nm and 805 nm, used to measure blood oxygen saturation levels.
- the relatively high-frequency oscillations 800 that occur in the signals due to the pumping of the cardiac or heart muscle, the more subtle rhythmic variations caused by respiration are readily identified within the signals by the addition of a signal envelope 820 .
- the pulse waveform signal generated by sensor assembly may be analyzed to interpret the performance of the cardio-vascular and pulmonary systems in a human being.
- FIGS. 16A and 16B illustrate a pulse volume waveform signal similar to pulse waveform signal 700 a of FIG. 12A .
- the pulse volume waveform signal of FIG. 16A has been labeled as follows to define areas of interest that are related to the pumping action of the heart:
- the pulse waveform signal generated by the sensor assembly may be used to produce a Myocardial Contractility Index or “Cardiac Index” and a Tissue Perfusion Index.
- Myocardial Contractility is the ability of the cardiac muscle to contract. The greater the ability of the cardiac muscle to contract, the greater the cardiac output.
- Tissue perfusion is related to the volume and flow of blood through the blood vessels. Tissue perfusion is related to ability of body tissues to efficiently exchange waste and nutrients with the blood and is related to the oxygen saturation levels.
- a cardiac index and a perfusion index may be developed from the pulse waveform signals generated by the sensor assembly.
- FIG. 17 illustrates a pulse volume waveform signal similar to pulse waveform signal 700 a of FIG. 12A .
- the microprocessor may be suitably programmed to determine the slope of the curve as well as the area under the curve associated with a single contraction or beat of the heart. This single contraction is represented by a time period from t 0 to t total .
- the maximum acceleration, determined by the upward slope of the curve represents the maximum contractility of the myocardium at a particular heart rate; The change in the slope can be used to develop the Myocardial Contractility Index.
- each of the above ratios may change and the rate of change may correlate to underlying heart disease.
- a small change in heart rate may cause a drastic change in the amount of oxygen being carried in the blood, which changes the efficiency of body tissues to exchange waste and nutrients with the blood.
- a Vascular Elasticity Index may also be developed from the same curve used to define the Myocardial Contractility Index and the Tissue Perfusion Index.
- Vascular elasticity is a measure of the flexibility of blood vessels. As the flexibility of the blood vessels increase or decrease, each of the above ratios may change and the rate of change may correlate to an underling constriction of the blood vessels leading to heart disease.
- the pulse waveform signal generated from the sensor assembly may be compared to a signal generated from an electrocardiogram (EKG).
- EKG electrocardiogram
- a traditional EKG is a measurement of the electrical activity of the heart. There may be cases where an EKG may be reflect the normal electrical activity of the heart, yet there is no actual pumping of blood from the heart. This is known in the art as electromechanical disassociation.
- a sensor assembly such as patch 400 or cuff 100 , may be attached to the skin or implanted within the body near or around a major artery such as the aorta. A signal will be generated by the sensor assembly from the flow of blood through the artery as described in previous embodiments. The signal generated by the sensor assembly measures the actual mechanical pumping of the heart as discussed previously.
- FIG. 18A illustrates the electrical activity of the heart, an EKG 900 , and a signal generated by the pumping action of the heart, the pulse waveform signal similar to 700 a.
- the two signals may be monitored concurrently to identify instances when the electrical activity of the heart, as evidenced by the EKG waveform, is present, yet there is no measurement of tissue perfusion by the sensor assembly, i.e., the heart is not pumping (see FIG. 18B ). This would be evidence of electromechanical disassociation. Electromechanical disassociation, if not recognized, may result in death. Also, both signals may be monitored on a particular person that requires the aid of a pacemaker to ensure that the heart is responding to the signals from the pacemaker.
- a health care professional may rely on the actual measurements of mean arterial pressure (see FIGS. 13A and 13B ), myocardial contractility (see FIG. 17 ), tissue perfusion (see FIG. 17 ), and vascular elasticity (see FIG. 17 ) as defined and discussed above to perform a diagnostic analysis or diagnosis of a person without having to rely on a calculation of the traditional diastolic and systolic blood pressure numbers.
- the measurements described above are all available signals generated from the sensor assemblies that detect the volume and flow of blood through the vessels.
- a health care professional may rely on the actual measurements rather than the calculated systolic and diastolic blood pressure numbers to provide a more precise and accurate diagnosis of the pulmonary system of any particular person.
- Databases of envelopes may also be created as described in previous embodiments based on the above measurements to develop a number diagnostic indexes such as the cardio index, tissue perfusion index, and vascular elasticity index. These databases may be developed either generically across a population of people based on age, gender, size, etc., or specific to one person based on previous physicals and signal monitoring. The above indexes along with a measurement of mean arterial pressure may be used to quickly, precisely, and accurately diagnose a potentially fatal pulmonary issue if left untreated and more importantly undiscovered.
- a sensor assembly such as patch 400 or similar device may be adapted for use in an effort monitor the physical health of a person on the battlefield or in flight during a war or fighting situation.
- the embodiments described above to generate pulse waveform signals to monitor vital sign parameters may be employed to continuously or periodically monitor a person's physical health in battle.
- radio frequency, ultrasonic, or optical based signals may be employed to transmit signals between an individual soldier and a central command center monitoring all soldiers.
- Low power devices such as patch 400 may be directly interfaced onto the soldier's outer skin or incorporated into their uniforms or gear.
- the sensor assemblies of the present invention provides significant advantages over prior art systems and methods by providing the ability to monitor blood parameters, such as blood pressure, heart rate, oxygen saturation and respiration rate, in a near-continuous manner through analysis of a single optical signal. Furthermore; the non-invasive features of the present invention make it an ideal blood parameter monitor for use with neonates. Traditional monitoring devices, such as, for example, ausculatory and prior oscillometric-based methods for monitoring blood pressure, are frequently ineffective with subjects such as neonates due to their relatively small size.
- the sensor assemblies of the present invention are capable of accurately monitoring blood parameters in a relatively small biological entity by transmitting an optical signal through the limb or head of the biological entity. Indeed, the smaller the biological entity, the less tissue the optical signal has to traverse, resulting in a stronger signal that is received by the photodetector and subsequently analyzed to determine vital sign parameters such as, for example, blood pressure.
- the present invention has been drawn to a system and method for monitoring certain vital sign parameters of a neonate by directing an optical signal through the tissue of the neonate's limb or forehead. According to the embodiments discussed up until now, this is accomplished through the use of a cuff-based or patch-based structure that wraps around a limb or is position on a head, or, alternatively, into which a limb is inserted, the cuff and patch structure thereby retaining a light source and photodetector in proximity to the limb and head.
- the present invention can be implemented in numerous other configurations that would be as equally effective in providing near-continuous monitoring of certain blood parameters of a neonate.
- no such type of cuff structure is utilized.
- the light source and photodetector are selectively retained in proximity to the limb through the use of some form of clip or clamping structure that does not encircle the entire limb or, alternatively, through the use of a removable adhesive.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Optics & Photonics (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Abstract
An apparatus for monitoring vital sign parameters in a biological entity is disclosed. In an embodiment, the apparatus includes at least one light source for transmitting light through the biological entity and at least one photodetector for receiving light transmitted through the biological entity. At least one light source and at least one photodetector are configured to be positioned proximate the biological entity in a manner that does not significantly impede blood flow through the biological entity. A signal is generated in response to the transmittance or reflectance of light through the biological entity. The signal corresponds to at least one characteristic of the generally unimpeded blood flow through the biological entity. The apparatus also includes a control system configured to analyze the signal to determine vital sign parameters in the biological entity. A method for monitoring vital sign parameters in a biological entity is also provided.
Description
- The present invention relates to medical devices and, more particularly, to apparatuses and methods for non-invasively monitoring vital sign parameters of a biological entity, such as a neonate.
- A basic requirement in determining the health of a human adult or neonate is to measure certain vital sign parameters, such as blood pressure, pulse rate, blood oxygen saturation, and respiratory rate. For example, measuring blood pressure in a human adult is typically accomplished using either an oscillometric-based method or an auscultatory method, both of which traditionally involve the application of an inflatable blood pressure cuff around the arm of the subject. While oscillometric-based and auscultatory methods are easily implemented with a human adult, these methods are not well suited for subjects such as neonates due to their diminutive size and inability to comprehend and cooperate with the procedure.
- Beyond the inability to accurately monitor vital sign parameters in a small subject, traditional methods of measuring vital sign parameters are generally carried out on a periodic basis, as opposed to providing near-continuous monitoring. This is because traditional methods of monitoring generally required that the subject be disturbed in some manner. For example, in monitoring blood pressure, blood flow through the subject's body member was occluded, through inflation of the blood pressure cuff, in order to measure blood pressure. Inflation of the blood pressure cuff may be disturbing to a neonate, particularly during their rest if performed on a periodic basis.
- Accordingly, a need exists for apparatuses and methods for monitoring vital sign parameters, such as blood pressure, oxygen saturation, pulse rate, and respiration, regardless of whether the subject is a human adult, a neonate or some other biological entity. The apparatuses and methods should be easily implemented and obtain accurate results, as well as be carried out in a near-continuous manner so as to allow for monitoring without disturbing the subject. Also, the apparatuses and methods should be employed such that any biological entity, regardless of size, may be monitored.
- The present invention provides apparatuses for monitoring vital sign parameters of a biological entity. In one embodiment of the invention, the apparatuses include at least one light source for transmitting light through the biological entity and at least one photodetector for receiving light transmitted through the biological member. At least one light source and at least one photodetector are configured to be positioned proximate the biological entity in a manner that does not significantly impede blood flow through the biological entity. A signal is generated in response to the transmittance or reflectance of light through the biological entity. The signal corresponds to at least one characteristic of the generally unimpeded blood flow through the biological member. The apparatuses also include a control system configured to analyze the signal to determine blood pressure, oxygen saturation, pulse rate, perfusion index, cardiac index, vascular elasticity, and respiration, among other blood parameters, of the biological entity.
- The present invention also provides methods for monitoring vital sign parameters in a biological entity. In one embodiment, the method includes positioning at least one sensor assembly proximate the biological entity. A signal is generated by at least one sensor assembly that corresponds to at least one characteristic of the blood flow through the biological entity. The signal is analyzed to determine blood pressure, oxygen saturation, pulse rate, perfusion index, cardiac index, vascular elasticity, and respiration, among other blood parameters, of the biological entity.
- Embodiments of the invention will now be described, by way of example, with reference to the accompanying drawings, wherein:
-
FIG. 1A depicts, from a first perspective, a trans-illuminating cuff according to an embodiment of the invention; -
FIG. 1B is a cross-sectional view of the trans-illuminating cuff ofFIG. 1A ; -
FIG. 2 is a view of the trans-illuminating cuff ofFIG. 1A from a second perspective; -
FIG. 3 is a depiction of the trans-illuminating cuff ofFIG. 1A from a third perspective; -
FIG. 4 is a perspective view of a trans-illuminating cuff according to another embodiment of the invention; -
FIGS. 5A and 5B depict two possible optical paths that may be established through a biological member; -
FIG. 6A is a perspective view of the trans-illuminating cuff ofFIG. 1A applied to the arm of a neonate; -
FIG. 6B , is a perspective view of the trans-illuminating cuff ofFIG. 1A applied to the finger of an adult; -
FIG. 7 depicts, from a first perspective, a trans-illuminating patch according to another embodiment of the invention; -
FIG. 8 is a view of the trans-illuminating patch ofFIG. 7 from a second perspective; -
FIG. 9 is a front elevational view of the trans-illuminating patch ofFIG. 7 applied to the head and neck of an adult; -
FIG. 10 is a perspective view of a trans-illuminating clip according to another embodiment of the invention; -
FIG. 11 is a block diagram of a vital sign parameter control system incorporating the trans-illuminating cuff ofFIG. 1A and the trans-illuminating patch ofFIG. 7 ; -
FIG. 12A are exemplary pulse waveform signals obtained from the use of the trans-illuminating cuff ofFIG. 1A and the-trans-illuminating patch ofFIG. 7 with a biological member, such as the arm or head of a neonate; -
FIGS. 12B-12D are exemplary pulse waveform signals ofFIG. 12A that have been positioned within an analysis envelope; -
FIGS. 13A and 13B are further exemplary pulse waveform signals illustrating optical oscillometric blood pressure measurements with a vital sign monitor; -
FIG. 14 is a graph that illustrates the spectral characteristics of hemoglobin (Hb) and oxygenated hemoglobin (HbO2); -
FIG. 15 illustrates the presence of respiratory variations in the graphs of transmittance of light of first and second wavelengths; -
FIGS. 16A and 16B is an exemplary pulse waveform signal that has been labeled to define areas of interest that are related to the pumping action of a heart; -
FIG. 17 is an enlarged exemplary pulse waveform signal ofFIG. 12A to illustrate transition points of the signal; and -
FIGS. 18A and 18B are exemplary electrocardiogram signals and an exemplary pulse waveform signals shown for comparison purposes. - One embodiment of the present invention will now be described with reference to
FIGS. 1-3 . Illustrated inFIG. 1A is one side of a member trans-illuminatingcuff 100 for monitoring certain vital sign parameters of a biological entity. A particular biological entity that is discussed in the several embodiments is a newborn, neonate, or infant (collectively referred to as “neonate” for the remainder of the application and understood to represent not only a person in their early stages of life, but any person of relatively diminutive size, such as an infant, regardless of age). Although the following describes these several embodiments in use with a neonate, it must be understood that these embodiments may also be used to monitor the vital signs of other biological entities such as an adult person or animals (e.g., canines and primates). - In the illustrated embodiment,
cuff 100 includes aflexible support member 122 that can be readily wrapped or applied around an arm, leg, finger or other appendage (collectively referred to as a “limb” for the remainder of the application) of a biological entity. Incorporated within or mounted upon one side ofcuff 100 is at least onelight source 132 and at least onephotodetector 134 positioned to diametrically opposelight source 132 whencuff 100 is applied over a limb of a neonate. One suitable type of light source for use incuff 100 is a light emitting diode (LED), such as the type L660/805/975-40D00, available from Epitex, Kyoto, Japan, and a suitable photodetector is a photoresistor or photodiode, such as the QSD723 photoresistor available from QT Optoelectronics. However, other light sources and photodetectors for generating and receiving one of more frequencies of light may also be used incuff 100 without departing from the spirit and scope of the invention. - In the embodiment illustrated in
FIGS. 1-3 ,cuff 100 includes twolight sources cuff 100 so as to opposephotodetector 134 whencuff 100 is applied over a limb 200 (see, e.g.,FIG. 5A ). This dual light source configuration provides for increased transmission of light through the tissue bed and around abone 210 oflimb 200. Alternatively,light source 132 andphotodetector 134 may be positioned side-by-side to allow for the monitoring of blood parameters based not on light transmitted directly from thelight source 132 to thephotodetector 134, but instead on light transmitted into the tissue of thelimb 200 bylight source 132 and subsequently reflected back to photodetector 134 (see, e.g.,FIG. 5B ). - As illustrated in
FIG. 2 ,cuff 100 also includes anattachment device 138 for securingcuff 100 tolimb 200 of a neonate. According to the present embodiment,attachment device 138 includes a cinch-loop 140 attached to afirst end 142 of theflexible support member 122 through which asecond end 144 extends whencuff 100 is applied to the limb of a neonate. In the illustrated configuration, hook-and-loopstyle fastener components flexible support member 122. Oncecuff 100 is applied tolimb 200 of a neonate,fastener components cuff 100 in its wrapped position without significantly impeding the flow of blood through the limb (see, e.g.,FIGS. 6A and 6B ). In an alternative embodiment,cuff 100 may lack a cinch-loop 140, relying entirely on hook-and-loopstyle fastener components cuff 100. In addition, further embodiments may forgo the hook-and-loopstyle fastener components - In addition to
light source 132 andphotodetector 134,cuff 100 may optionally include one or moreinflatable bladders 124 that are either incorporated intocuff 100 or mounted to an interior side ofcuff 100. Upon placingcuff 100 aroundlimb 200 of a neonate,bladder 124 may be inflated to a relatively low pressure level that would aid in securingcuff 100 in position while not significantly impeding the flow of blood throughlimb 200. Alternatively, as will be discussed later, it may be desirable to include abladder 124 that may be inflated to a sufficiently high enough pressure level to temporarily obstruct the flow of blood throughlimb 200. - Regardless of either of the above intended functions, the addition of a
bladder 124 tocuff 100 may be done in such a manner as to ensure thatlight source 132 andphotodetector 134 optically communicate withlimb 200. For illustrative purposes, consider the following two embodiments. In a first embodiment,bladder 124 mounts to an interior side ofcuff 100 overlight source 132 andphotodetector 134. To ensure that neitherlight source 132 norphotodetector 134 are obstructed,bladder 124 may be fashioned from a material, such as polyurethane, which is optically transparent to the wavelength of light emitted bylight source 132 and to whichphotodetector 134 is sensitive. Alternatively, according to another embodiment,cuff 100 may incorporate abladder 124 in such a manner that whenbladder 124 is inflated,light source 132 andphotodetector 134 remain in contact with or proximal tolimb 200. This can be accomplished, for example, by configuringcuff 100 so thatlight source 132 andphotodetector 134 are mounted not uponflexible support member 122, but uponbladder 124. - According to another embodiment of the invention,
flexible support member 122 may include a generally cylindrical sleeve (not illustrated) that may be slipped around thelimb 200 of a neonate. To accommodatelimbs 200 of different sizes, the generally cylindrical sleeve may possess elastic characteristics that allow it to stretch and contract as alimb 200 is inserted into the sleeve. The contractile forces generated by the sleeve as it is slipped around alimb 200 also serve to secure the placement of the sleeve without significantly impeding blood flow through the limb. - In still another embodiment of the invention,
flexible support member 122 may include a generally cylindrical sleeve that does not have elastic characteristics. Instead, at least onebladder 124 may be incorporated into the sleeve or mounted upon the interior surface of the sleeve. Once sleeve is slipped around thelimb 200 of a neonate,bladder 124 may be inflated with sufficient pressure to secure the sleeve around the limb without significantly impeding blood flow. If desired, the bladder may also be inflated to a pressure exceeding the systolic blood pressure of the subject, thereby substantially obstructing the flow of blood throughlimb 200. - According to yet another embodiment of the invention, an example of which is illustrated in
FIG. 4 , a trans-illuminatingcuff 300 is provided that includes a rigid orsemi-rigid housing 310, such as a plastic tube, into whichlimb 200 of the neonate can be inserted. Similar to the previous embodiments, at least onelight source 332 and at least onephotodetector 334 are incorporated into or mounted uponhousing 310 in such a manner that, upon insertion oflimb 200,light source 332 may transmit light through the tissue oflimb 200, with the transmitted light subsequently being received byphotodetector 334. - To ensure an adequate fit with different limb sizes, a resilient sleeve or layer of
material 320 may be incorporated with, or mounted onto, the interior surface ofhousing 310.Resilient layer 320 may include, for example, foam rubber and other materials that readily compress upon being pressed againstlimb 200. In this manner, a fixeddiameter housing 310 may accommodate various limb sizes, theresilient layer 320 compressing and expanding as needed to generally conform to the shape oflimb 200. As will be appreciated,resilient layer 320 may be configured so that it does not obstruct the transmission of light fromlight source 332 into the tissue oflimb 200, nor interfere with the reception of light byphotodetector 334. This can be accomplished through selective placement ofresilient layer 320 or, alternatively, by makingresilient layer 320 out of a material that is optically transparent to the wavelengths) of light transmitted bylight source 332 and received byphotodetector 334. In another configuration,light source 332 andphotodetector 334 may be positioned onresilient layer 320 instead ofhousing 310. In this manner,resilient layer 320 aids in positioning thelight source 332 andphotodetector 334 in close proximity tolimb 200 aslayer 320 expands and contracts in response to the presence oflimb 200. - In another configuration,
housing 310 ofcuff 300 may be configured so thatresilient layer 320 is supplemented or replaced by at least one bladder (see, e.g., bladder 124) that are selectively inflatable to a pressure level sufficient to holdhousing 310 in place onlimb 200 without significantly impeding the flow of blood throughlimb 200. For reasons that will be described below, the bladder(s) may also be selectively inflated to a pressure exceeding the systolic blood pressure of the neonate, thereby substantially obstructing the flow of blood throughlimb 200. - According to another embodiment of the invention, an example of which is illustrated in
FIGS. 7 and 8 , a trans-illuminatingpatch 400 is provided. Similar to previous embodiments, at least onelight source 432 and at least onephotodetector 434 are incorporated into or mounted uponpatch 400. Unlike the previous embodiments,patch 400 may be placed on any location or position of the neonate's body and used to monitor the vital sign parameters.Limb 200 may be used for placement, but is not required.Patch 400 may be positioned on the neonate's head, chest, neck, thigh, or other suitable location to monitor vital sign parameters (see e.g.,FIG. 9 ,patch 400 is positioned on the head and neck of an adult person).Patch 400 may be attached to the particular area of the body with adhesives, reusable or otherwise, or some other attachment device such as a bandage, headband, or the like. -
Patch 400 may be positioned on the neonate in relatively flat locations rather than encirclinglimb 200 likecuffs light source 432 andphotodetector 434 may be positioned side-by-side to allow for monitoring of vital sign parameters based not on light transmitted directly from thelight source 432 tophotodetector 434, but instead on light transmitted into the tissue of the neonate's body bylight source 432 and subsequently reflected back to photodetector 434 (see, e.g.,FIG. 5B ). - In addition to
light sources 432 andphotodetector 434,patch 400 may also include one or more inflatable bladders (see, e.g., bladder 124) that are incorporated intopatch 400. The bladders may be mounted to patch 400 such that the bladders may be between the neonate and thepatch 400. In this case, the bladders may be fashioned from a material, such as polyurethane, which is optically transparent to the wavelength of light emitted bylight sources 432 and to whichphotodetector 434 is sensitive. As will be discussed later, the bladders may be selectively inflated to a pressure exceeding the systolic blood pressure of the neonate, thereby substantially obstructing the flow of blood through that particular area of the neonate's body. - According to another embodiment of the invention, an example of which is illustrated in
FIG. 10 , a trans-illuminatingclip 500 is provided. Similar to previous embodiments, at least onelight source 532 and at least onephotodetector 534 are incorporated into or mounted uponclip 500.Clip 500 may be secured to smaller portions of the body such as earlobes, fingers, toes, and the like, and used to monitor the vital sign parameters. (see e.g.,FIG. 9 ,clip 500 is positioned on the earlobe of an adult person).Clip 500 includes anattachment device 538 that includes a biasingmember 540 such as a spring, resilient rubber, or the like, to ensure thatlight source 532 andphotodetector 534 remain proximate the tissue of the neonate. - With reference now to
FIG. 11 , acontrol system 600 of the present invention is shown. In an embodiment,control system 600 includes aprocessor 605 that controls, among other things, operation of light sources (e.g., 132, 432) and photodetectors (e.g., 134, 434) in a sensor assembly (e.g. cuff 100, patch 400). Although the sensor assembly employing light sources and photodetectors is the preferred means of generating a signal relating to vital sign parameters, it must be understood that equivalent means for generating signals relating to vital sign parameters may be employed such as ultrasound or the like. Althoughcontrol system 600 is discussed controlling two sensor assemblies, it should be understood thatcontrol system 600 may control multiple channels so that multiple sensor assemblies, that are positioned on a neonate, may be used in monitoring vital sign parameters. - During vital sign parameter measurements, for example, in the measuring of blood pressure, the microprocessor energizes the light sources continually. When activated, photodetectors convert the light transmitted through the tissue in
limb 200 or reflected in head 450 (or other part of the body such as the neck, chest, or thigh) into a corresponding electronic signal. This electronic signal is subsequently supplied toprocessor 605 for analysis after being optionally passed throughamplifiers display screen 620. In the embodiment illustrated inFIG. 11 ,processor 605 is depicted as being separate from the sensor assemblies. However, in an alternative embodiment,control system 600 may be more integrated into the sensor assemblies, with one or more of the components, includingprocessor 605, being incorporated into the sensor assemblies. - The sensor assemblies may also communicate with
pumps pumps processor 605 and convey air into the inflatable bladders throughinflation tubes Pressure transducers control system 600 for monitoring the pressure ininflation tubes processor 605. Suitable transducers are available from Cobe Labs, Littleton, Colo. - Operation of the sensor assemblies in conjunction with
control system 600 to monitor certain vital sign parameters of a neonate, will now be discussed with reference toFIG. 12A . Before any vital signs may be monitored, a first sensor assembly (e.g., cuff 100) is secured aroundlimb 200 of a neonate (see, e.g.,FIG. 6A ) and a second sensor assembly (e.g., patch 400) is secured to the head of a neonate (see, e.g.,FIG. 9 ). Once appropriately positioned,control system 600 activates the sensor assemblies by operating or energizing light sources (e.g., 132, 432) and photodetectors (e.g., 134, 434). Once energized, the light sources begin to transmit light of a first wavelength or frequency. This transmitted light, representing an optical signal, passes through the skin and into the tissue of limb 200 (see, e.g.,FIG. 5A ) and passes through the skin and is reflected off the skull in head 450 (see, e.g.,FIG. 5B ). The optical signal continues to travel through the tissue making uplimb 200 and head 450, including, for example, various types of skin tissue, muscle, and blood vessels. As the optical signal travels through these various constituenttissues comprising limb 200 and head 450, portions of the signal are deflected or absorbed. The remainder of the optical signal that makes it through the tissue oflimb 200 is received by the photodetector. The remainder of the optical signal that is reflected through the tissue of head 450 is received by the photodetector. The photodetectors subsequently convert the optical signals into electric signals to be sent to controlsystem 600. - At any specific point in time, this electric signal produced by the photodetectors represents the transmittance (T) of the optical signal through the tissue of
limb 200 and the reflectance (R) through the tissue of head 450 at that moment in time. This transmittance (T) or reflectance (R) of the optical signal is not constant, but continuously fluctuates due to ongoing changes occurring in the tissue oflimb 200 and head 450, including without limitation, changes in blood flow. Specifically, blood is distributed throughoutlimb 200 and head 450 by a variety of blood vessels, including, for example, arteries and arterioles. The rate and volume of blood flow through these vessels is largely dependent on blood pressure levels, which in turn are dependent on the pumping action of the heart as well as the blood vessels themselves, some of which constrict or dilate depending on the current biological state of the subject. Accordingly, the transmittance (T) of the optical signals through the tissue oflimb 200 and reflectance (R) of the optical signals through the tissue of the head 450 are dependent on volumetric changes in blood flow, which, in turn, are dependent on blood pressure levels. Consequently, analysis of the electric signals, which represent variations in transmittance (T) or reflectance (R) of the optical signals due to volumetric changes in blood flow, permits the determination of several vital sign parameters, including without limitation, blood pressure oxygen saturation, pulse rate, perfusion index, cardiac index, vascular elasticity, and respiration. - Illustrated in
FIG. 12A is a graphical representation ofexemplary signals limb 200 and energizing the light source and the photodetector. Asimilar pulse waveform 700 b is obtained after securing the second sensor assembly to head 450 and energizing the light source and the photodetector. The rhythmic pattern of fluctuations or oscillations within pulse waveform signals 700 a, 700 b represent changes in the volumetric flow of blood throughlimb 200 or head 450 primarily due to the pumping or “beating” action of the human heart. - Subsequent analysis of pulse waveform signals 700 a, 700 b permit the determination of certain blood parameters that influence the flow of blood, such as, for example, mean arterial blood pressure, diastolic blood pressure and systolic blood pressure. This determination is possible due to the relationships, as discussed above, between transmittance (T) of the optical signal and between reflectance (R) of the optical signal, volumetric changes in blood flow, and blood pressure levels. In an embodiment of the present invention, analysis of pulse waveform signals 700 a, 700 b includes the application of one or more algorithms that manipulate the data of pulse waveform signals 700 a, 700 b in accordance with one or more predefined relationships that exist between transmittance (T) and reflectance (R) of the optical signal, blood flow and blood pressure levels. This is further discussed below.
- Now referring to
FIGS. 12B-12D , the microprocessor may be suitably programmed to generate anenvelope 702 from the pulse waveform signal.Envelope 702 is comprised of alower band 704 andupper band 706 that may be positioned around subsequent pulse waveform signals.Envelope 702 may be used to further aid health care professionals in the near continuous monitoring of a neonate's vital sign parameters and for diagnostic analysis. -
Microprocessor 605 may generateenvelope 702 from pulse waveform signal 700 a by using a signal sampling technique that is known in the art of signal processing. As the microprocessor generates a pulse waveform signal based on the electrical signal received from the sensor assembly (e.g., cuff, patch, clip, or other like device) used to monitor the neonates vital sign parameters, the microprocessor may be programmed to “sample” the pulse waveform signal periodically. Sampling the pulse waveform signal produces a second signal that may be similar to the original pulse waveform signal. The number of samples taken and the time period between samples will determine how closely the sampled signal resembles the original pulse waveform signal taken from the cuff, patch or other like device. Once the sample signal has been generated, the microprocessor may be programmed such thatlower band 704 andupper band 706 may be developed from the sampled signal, as determined by a healthcare professional, by adjusting the signal gain to produceenvelope 702. - For example,
FIG. 120 illustratesenvelope 702 that is a set of simple limit bars (lower band 704 and upper band 706) that are based on a sampled electrical signal from the sensor assembly. In this instance, microprocessor samples the pulse waveform signal at only a few points to identify the peak value of the pulse waveform signal. The microprocessor then sets the lower and upper bands of the envelope based upon the peak value or as directed by a healthcare professional. InFIG. 12C ,envelope 702 more closely resembles the pulse waveform signal that was generated by the microprocessor from the electrical signal received from the sensor assembly. The envelope inFIG. 12C is based on more frequent sampling of the pulse waveform signal than the envelope inFIG. 12B . The envelope inFIG. 12D is based on an even greater frequency of sampling of the pulse waveform signal then the envelope inFIG. 12C so that the lower and upper bands more closely resemble the actual pulse waveform signal. - The sampling period of the microprocessor may be adjusted to be used in the manner determined by the health care professional. The greater the frequency of the sampling period, the greater the number of sampling points generated, and the more the envelope will resemble the actual electrical signal from the sensor assembly. In this manner the health care professional will have greater precision when employing the use of an envelope in a diagnostic analysis or a near continuous monitor mode.
- Once
lower band 704 andupper band 706 ofenvelope 702 have been determined, the health care professional myemploy envelope 702 for a number of continuous monitoring and diagnostic analysis techniques. For example, an audible alert may be incorporated intocontrol system 600 such that during continuous monitoring of a neonate with sensor assemblies, an alarm may be sounded if the incoming electrical signal crosses eitherlower band 704 orupper band 706 indicating a unwanted change in vital sign parameters. - Also, after the signal envelopes have been established,
pulse waveform signal 700 a may be analyzed through a process of comparingsignal 700 a to a number of previously established pulse waveform signals that have already been associated with one or more known vital sign measurements. Specifically, the present analysis method involves the creation of a database of reference envelopes based on previous pulse waveform signals and corresponding blood flow characteristics associated with the reference signals. Each individual envelope characteristic in the database or, alternatively, a combination of two or more envelope characteristics, is then associated with one or more vital sign measurements, such as, for example, blood pressure respiration, and heart rate. Apulse waveform signal 700 a undergoing analysis is evaluated for one or more identifiable and defining characteristics. These defining characteristics in the evaluatedpulse waveform signal 700 a are compared to the established envelope characteristics maintained in the database. If this comparison meets certain predetermined criteria between the characteristics of thepulse waveform signal 700 a being analyzed and the specific reference characteristics stored in the database, it can be assumed that the blood parameters associated with pulse waveform signal 700 a are the same as the known blood parameters associated with the selected reference envelopes stored in the database. The known blood parameters corresponding to the monitoredwaveform signal 700 a may then be presented to the healthcare provider, such as ondisplay 620. - Additionally, the envelopes developed from the pulse waveform signals may be generated and stored in databases for an entire population. A generic database of envelopes may be developed that may be based on age, gender, size, or any number of attributes. By employing the use of these databases, health care professionals may be able to establish a base line reading for those people who have not had a medical physical in quite some time. Rather than taking several months or years to establish a baseline, a generic pulse waveform envelope baseline can be drawn from the database based on parameters such as size, age, and gender, and the person's pulse waveform signal monitored against established envelopes. While, every person will still require an individual assessment, irregularities may be identified in advance with the use of the generic database of envelopes that closely correspond to a particular person's size, age, gender, etc.
- For those people that do visit their healthcare professional regularly, an individual database of envelopes may be developed for future diagnostic analysis. One example may involve a person who visits his health care professional for regular physicals. Each time the person returns his yearly physical, the healthcare professional can access his previous envelopes to be used in comparison purposes with the new pulse waveform signal that is presently being generated. The healthcare professional may be alerted to potential physiological problems if the new signal passes outside the envelope indicating a change in the person's vital sign parameters. In another example, a person may find himself in an accident where he is unconscious and cannot communicate with onsite health care professionals. Identification information about the victim can be entered into a computer and the onsite professionals can access the victim's database of pulse waveform signal envelopes to identify any of the victim's vital sign parameter abnormalities that may require attention prior to treating the victim. In this manner, people may receive a relatively quick and accurate diagnosis, which in turn leads to quick and more importantly the correct form of treatment.
- Physiological markers that may be monitored and measured by these embodiments may include, but are not limited to, glucose levels, lactate, C-reactive protein, cytokines, white blood cell counts, and gene or protein expression in-vivo. These biological markers not only provide insight into the health status, but also address pre-symptomatic activity due to infection, chemical or biological agent exposure.
-
Microprocessor 605 may also compare pulse waveform signal 700 a produced from the first sensor assembly positioned around limb 200 (see e.g.,FIGS. 6A and 6B ), withpulse waveform signal 700 b produced from the second sensor assembly positioned on head 450 (see e.g.,FIG. 9 ). As discussed above, a database of envelope signals may be created for comparison purposes. The health care provider may monitor these waveforms-taken from different areas of the subject to diagnosis possible internal biological problems that may be found between the monitoring devices. Also, the two separate sensor assemblies may be used in conjunction with one another for vital sign comparison purposes and analysis of the neonate. - In addition to the embodiments discussed above, the sensor assembly may also be configured to actively measure blood pressure of a subject through an oscillometric-based method. According to this embodiment, the sensor assembly may include at least one inflatable bladder selectively operable to occlude blood flow in
limb 200 or head 450 upon inflation to a sufficiently high enough pressure. An illustrative example of this embodiment will now be discussed with reference toFIGS. 13A and 13B , which depicts apulse waveform signal 710 along with agraph 720 of corresponding sensor assembly pressure. As in the previous embodiments, apulse waveform signal 710 is obtained by applying the sensor assembly aroundlimb 200 or to head 450 of the subject and then subsequently energizing the light source to transmit an optical signal through the tissue of the limb or the head to the photodetector. When the bladders are in a deflated state, and thus not significantly impeding the flow of blood throughlimb 200 or head 450, the sensor assembly will generate a firstpulse waveform signal 710 a that is similar in nature to the pulse waveform signals 700 a, 700 b obtained in the previously discussed embodiment of the invention. - At time B, pump 630 a, 630 b (illustrated in
FIG. 11 ) activates, thereby increasing the pressure in the bladders, as illustrated inFIGS. 13A and 13B bygraph segment 722. As the bladder pressure increases, sensor assembly begins to constrictlimb 200 or head 450. This constriction causes at least a partial pinching of the blood vessels running through the limb or the head, which, in turn, impedes blood flow through the blood vessels. During this stage of increasing bladder pressure, the pulses or oscillations in thepulse waveform signal 710 b first increase in amplitude, reach a maximum, and then decrease in amplitude. Once the pressure in the bladder exceeds the systolic blood pressure; substantially all blood flow through the limb or head is terminated. The essential lack of blood flow throughlimb 200 or head 450 during this time period results in a near constant level of transmittance (T) of the optical signal traveling through the tissue oflimb 200 or reflectance (R) of the optical signal traveling through the tissue of head 450. As a result of this near constant transmittance (T) or reflectance (R), the pulse waveform signal becomes nearly constant (see, e.g.,segment 710 c), exhibiting substantially no variances or oscillations in form. At time D, the bladder is allowed to deflate or depressurize at a predetermined rate, as indicated bygraph segment 726. The transition period DE in bladder pressure results in amplified oscillations or spikes in the pulse waveform signal (see, e.g.,segment 710 d). As the sensor assembly returns to an un-pressurized state, the oscillations in the pulse waveform signal (see, e.g.,segment 710 e) return to a substantially uniform level. - During both transient pressure stages, indicated in
FIG. 13B asstages segments envelope 715 may be generated based upon the transient signal. The positive peak of the envelope is at a point where the pulse amplitude reaches a maximum, identified as mean arterial blood pressure (Am) inFIGS. 13A and 13B . The maximum amplitude of the pulse is also a point where the bladder pressure is substantially equal to mean arterial blood pressure. Similarly, there exist points inwaveform signal segments - To illustrate the process described above, consider an example where it is assumed that the relationships between the oscillation amplitudes Am, Ad, and As may be mathematically represented by the equations:
-
A d /A m =X, and -
A s /A m =Y, - where X and Y are constants that are empirically determined based on certain characteristics of the subject, such as shape. Upon determination of oscillation amplitude Am through analysis of the pulse waveform signal, one can readily obtain oscillation amplitudes Ad and As. The points on the pulse waveform signal that correspond to oscillation amplitudes Ad and As are then identified, by interpolation if necessary. The relationship of Ad/Am is a fixed constant value while the relationship of As/Am may determined by a linear algorithm. Once these points in time are identified, the corresponding cuff pressures that exist at these two times and which correspond, respectively, to diastolic and systolic blood pressures, are readily determined.
- After a blood pressure has been determined through the use of the above algorithm, the steady state signal occurring after the deflation of the bladder will have the characteristics of the calculated blood pressure. The steady state signal (
e.g. graph segment 710 e) generated by the sensor assembly after the measurement of mean arterial pressure and deflation of the bladder, may be monitored in a near-continuous manner. The steady state signal generated after the deflation of the bladder is a signature of the measured mean arterial pressure and the calculated blood pressure. Rather than continuously monitoring blood pressure by inflating and deflating the bladder and disturbing the neonate, an envelope may be positioned aroundwaveform signal 710 e and then monitored for one or more predetermined signal characteristics, such as any substantial deviations or fluctuations occurring in the electrical signal that may cross either the lower or upper limit bands of the envelope and indicated an abnormal condition in the neonate. Providedpulse waveform signal 710 e remains in a steady state or near steady state condition, it may be assumed that the previously measured blood pressures levels correlating to the waveform signals 710 e have not substantially changed. If at any time the generated signal from the sensor assembly passes outside of the envelope,control system 600 may be programmed to trigger an alarm to notify health care professionals of the irregularity and/or perform a new blood pressure measurement and calculation as described above. - In this manner, an actual blood pressure measurement involving inflation of the bladder and subsequent analysis of the
pulse waveform signal 710 occurs only when changes in thewaveform signal 710 e indicate probable changes in blood pressure. In this way, continuous monitoring of blood pressure can be maintained without having the intrusive inflating and deflating of the bladder that may disturb the subject. - In addition to monitoring blood pressure, the sensor assembly may also provide near-continuous monitoring of the pulse or heart rate of the subject. This is accomplished in a manner similar to that previously discussed for providing near-continuous monitoring of blood pressures. Specifically, the sensor assembly is applied to a limb of the subject. If the sensor assembly includes one or more bladders, they should be deflated so as to not constrict the limb, and, consequently, impede blood flow. The light source and the photodetector are energized, generating a pulse waveform signal such as that illustrated in
FIG. 12 . A similar waveform signal may be generated by a sensor assembly located elsewhere on the subject such as the head. As previously discussed, the pulse waveform signals 700 a, 700 b are indicative of the volumetric changes occurring in the flow of blood through the limb or head. A typicalpulse waveform signal 700 will be characterized by a rhythmic pattern of fluctuations or oscillations in the signal. These oscillations represent near-continuous changes in the volumetric blood flow due to the pumping or “beating” action of the heart or cardiac muscle. Consequently, heart rate can be monitored by analyzing the waveform signal and determining the number of oscillations that occur within a predetermined period of time. - One primary function of blood is to transport oxygen to all tissues that make up the human body. The ability of blood to “carry” oxygen is due to the presence of hemoglobin (Hb) in the red blood cells. Oxygen brought in by the lungs temporarily binds to the hemoglobin (Hb). The oxygenated hemoglobin (HbO2) is then transported through the circulatory system, where it releases the oxygen to the cells that need it. Through use of a device known as a pulse oximeter, the oxygen saturation level, defined as the ratio of oxygenated hemoglobin (HbO2) to the total amount of hemoglobin (Hb+HbO2), can be measured and used to help assess the health of an individual.
- In an embodiment of the invention,
control system 600 may be configured to function as a pulse oximeter. In an embodiment, the sensor assembly, may be configured to generate light of two different wavelengths, such as, for example, 650 nanometers (nm) and 805 nm. As illustrated inFIG. 14 , hemoglobin (Hb) offers negligible transmission of light having a wavelength of 650 nm, while oxygenated hemoglobin (HbO2) readily allows for the transmission of light of 650 nm. In contrast, light having a wavelength of 805 nm transmits equally well though both hemoglobin (Hb) and oxygenated hemoglobin (HbO2). Accordingly, the transmission of light at 650 nm indicates a density of oxygenated hemoglobin (HbO2), while the transmission of light at 805 nm indicates a density of total hemoglobin (Hb+HbO2). - To measure blood oxygen saturation levels,
control unit 600 may be configured to alternately energize the two light sources of the sensor assembly in rapid succession, e.g., energizing the light sources at 200 pulses per second. In this manner, high-intensity, short duration pulses of first and second wavelengths of light are alternately transmitted through the tissue oflimb 200 or head 450. After passing through the tissue oflimb 200 or reflecting through the tissue of head 450, the alternating streams of light are received by the photodetectors, which, according to this embodiment, is a broadband photodetector capable of detecting both wavelengths. Alternatively, two separate narrow band photodetectors can be used with the sensor assembly, each photodetector capable of detecting light of one wavelength but not light of the other wavelength. The photodetectors convert the two alternating optical signals of different wavelengths into an electric signal representing the transmittance of two wavelengths.Processor 605 then analyzes the signal and determines the optical density for each of the two wavelengths. The ratio of first wavelength to second wavelength optical density is subsequently calculated and scaled to provide an output value corresponding to the percentage of oxygen saturation. As part of this process, the output value generated from the ratio of optical densities can be compared to an appropriate calibration curve programmed intoprocessor 605, such as, for example, in the form of a lookup table. The calibration curve relates optical density to a suspension, such as blood, and is derived from a variation of Beer's law that relates optical density to the concentration of a dissolved substance. - It may be advantageous to establish a baseline measurement of the transmittance of the two wavelengths of light before using the sensor assembly to measure blood oxygen saturation levels. In an embodiment of the invention, such a baseline measurement may be readily established if the sensor assembly includes at least one inflatable bladder. Specifically, the bladder may be inflated to a sufficiently high enough pressure so that it constricts the limb or head and drives or squeezes substantially all the blood out of the vessels that run within the portion of the limb or head located in the cuff or beneath the patch. The constriction of the limb or head ensures a lack of blood within the optical path established between the light source and the photodetector. An optical signal passed through these bloodless regions of the limb and head can then be assigned a 100% transmission value.
- To decrease the sensitivity of the sensor assembly systems to stray ambient light, the photodetectors can be synchronously energized with the light sources. This feature ensures that the photodetectors are turned on only when a light source is energized, and minimizes the amount of power drawn by the system, as well as the amount of heat generated by the light sources and photodetectors.
- The present invention may also be configured to monitor the respiration rate of a neonate. Specifically, blood oxygen saturation levels vary subtly with the breathing process, which includes the inspiration of oxygen and expiration of waste gases such as carbon dioxide. Unlike current commercially available pulse oximeters, the sensor assembly possesses short enough response times in its measuring capabilities to detect the subtle rhythmic changes that occur in blood oxygen saturation levels due to the breathing process. An example of this is illustrated in
FIG. 15 , which depicts an analog recording of the transmittance of the first and second wavelengths of light, such as 650 nm and 805 nm, used to measure blood oxygen saturation levels. Beyond the relatively high-frequency oscillations 800 that occur in the signals due to the pumping of the cardiac or heart muscle, the more subtle rhythmic variations caused by respiration are readily identified within the signals by the addition of asignal envelope 820. - In another embodiment of the present invention, the pulse waveform signal generated by sensor assembly (e.g.,
cuff 100 or patch 400) may be analyzed to interpret the performance of the cardio-vascular and pulmonary systems in a human being.FIGS. 16A and 16B illustrate a pulse volume waveform signal similar to pulse waveform signal 700 a ofFIG. 12A . The pulse volume waveform signal ofFIG. 16A has been labeled as follows to define areas of interest that are related to the pumping action of the heart: -
- A. Ventricular Contraction
- B. Ventricular Pressure Rises and Ventricular Volume Increases otherwise known as the QRS Complex
- C. When ventricular pressure exceeds aortic pressure, the aortic valve opens and blood is ejected into the aorta
- D. Isovolumetric Relaxation, muscle relaxes, but maintains volume, and pressure reduces
- E. The rate of volumetric change is shown by the slope of the curve
- F. Dicrotic Notch is observed and is caused by the closure of the aortic valve
- G. T-Wave (EKG) ends, ventricular pressure decreases, and volume increases
- H., I., J. Are the result of Ventricular Systole
- K., L. Relaxation of the Atrial Chamber provides this signal
Changes in A., B., and C. are understood to be related to the capacity of the heart to contract or “pump performance” while changes in E., F., G., and H. are understood to be related to vascular elasticity. The sampling and envelope technique described above in a previous embodiment may be employed to identify changes in the cardio-vascular and pulmonary systems of a particular human being as illustrated inFIG. 16B . The changes in the pulse volume waveform with respect to the envelope may be analyzed and interpreted by a health care professional to predict in advance heart disease and other cardio-vascular events that may be related to a heart attack.
- In yet another embodiment of the present invention, the pulse waveform signal generated by the sensor assembly, may be used to produce a Myocardial Contractility Index or “Cardiac Index” and a Tissue Perfusion Index. Myocardial Contractility is the ability of the cardiac muscle to contract. The greater the ability of the cardiac muscle to contract, the greater the cardiac output. Tissue perfusion is related to the volume and flow of blood through the blood vessels. Tissue perfusion is related to ability of body tissues to efficiently exchange waste and nutrients with the blood and is related to the oxygen saturation levels. A cardiac index and a perfusion index may be developed from the pulse waveform signals generated by the sensor assembly.
-
FIG. 17 illustrates a pulse volume waveform signal similar to pulse waveform signal 700 a ofFIG. 12A . The microprocessor may be suitably programmed to determine the slope of the curve as well as the area under the curve associated with a single contraction or beat of the heart. This single contraction is represented by a time period from t0 to t total. The maximum acceleration, determined by the upward slope of the curve represents the maximum contractility of the myocardium at a particular heart rate; The change in the slope can be used to develop the Myocardial Contractility Index. Also identified during the single contraction is a point on the curve where the slope of the curve is equal to zero, or tslope=0. The Tissue Perfusion Index may be represented by the following ratio in determining the area under the curve to the left of tslope=0: -
- As the heart rate increases or decreases, each of the above ratios may change and the rate of change may correlate to underlying heart disease. A small change in heart rate may cause a drastic change in the amount of oxygen being carried in the blood, which changes the efficiency of body tissues to exchange waste and nutrients with the blood.
- A Vascular Elasticity Index may also be developed from the same curve used to define the Myocardial Contractility Index and the Tissue Perfusion Index. The Vascular Elasticity Index may be represented by the following ratio in determining the area under the curve to the right of tslope=0:
-
- Vascular elasticity is a measure of the flexibility of blood vessels. As the flexibility of the blood vessels increase or decrease, each of the above ratios may change and the rate of change may correlate to an underling constriction of the blood vessels leading to heart disease.
- In another embodiment of the present invention, the pulse waveform signal generated from the sensor assembly may be compared to a signal generated from an electrocardiogram (EKG). A traditional EKG is a measurement of the electrical activity of the heart. There may be cases where an EKG may be reflect the normal electrical activity of the heart, yet there is no actual pumping of blood from the heart. This is known in the art as electromechanical disassociation. In this particular embodiment, a sensor assembly, such as
patch 400 orcuff 100, may be attached to the skin or implanted within the body near or around a major artery such as the aorta. A signal will be generated by the sensor assembly from the flow of blood through the artery as described in previous embodiments. The signal generated by the sensor assembly measures the actual mechanical pumping of the heart as discussed previously.FIG. 18A illustrates the electrical activity of the heart, anEKG 900, and a signal generated by the pumping action of the heart, the pulse waveform signal similar to 700 a. The two signals may be monitored concurrently to identify instances when the electrical activity of the heart, as evidenced by the EKG waveform, is present, yet there is no measurement of tissue perfusion by the sensor assembly, i.e., the heart is not pumping (seeFIG. 18B ). This would be evidence of electromechanical disassociation. Electromechanical disassociation, if not recognized, may result in death. Also, both signals may be monitored on a particular person that requires the aid of a pacemaker to ensure that the heart is responding to the signals from the pacemaker. - In yet another embodiment of the present invention, a health care professional may rely on the actual measurements of mean arterial pressure (see
FIGS. 13A and 13B ), myocardial contractility (seeFIG. 17 ), tissue perfusion (seeFIG. 17 ), and vascular elasticity (seeFIG. 17 ) as defined and discussed above to perform a diagnostic analysis or diagnosis of a person without having to rely on a calculation of the traditional diastolic and systolic blood pressure numbers. The measurements described above are all available signals generated from the sensor assemblies that detect the volume and flow of blood through the vessels. A health care professional may rely on the actual measurements rather than the calculated systolic and diastolic blood pressure numbers to provide a more precise and accurate diagnosis of the pulmonary system of any particular person. - Databases of envelopes may also be created as described in previous embodiments based on the above measurements to develop a number diagnostic indexes such as the cardio index, tissue perfusion index, and vascular elasticity index. These databases may be developed either generically across a population of people based on age, gender, size, etc., or specific to one person based on previous physicals and signal monitoring. The above indexes along with a measurement of mean arterial pressure may be used to quickly, precisely, and accurately diagnose a potentially fatal pulmonary issue if left untreated and more importantly undiscovered.
- In another embodiment of the present invention, a sensor assembly, such as
patch 400 or similar device may be adapted for use in an effort monitor the physical health of a person on the battlefield or in flight during a war or fighting situation. The embodiments described above to generate pulse waveform signals to monitor vital sign parameters may be employed to continuously or periodically monitor a person's physical health in battle. Rather than being connected directly to controlsystem 600 as described in previous embodiments, radio frequency, ultrasonic, or optical based signals may be employed to transmit signals between an individual soldier and a central command center monitoring all soldiers. Low power devices such aspatch 400 may be directly interfaced onto the soldier's outer skin or incorporated into their uniforms or gear. - It will be appreciated from the above description the sensor assemblies of the present invention provides significant advantages over prior art systems and methods by providing the ability to monitor blood parameters, such as blood pressure, heart rate, oxygen saturation and respiration rate, in a near-continuous manner through analysis of a single optical signal. Furthermore; the non-invasive features of the present invention make it an ideal blood parameter monitor for use with neonates. Traditional monitoring devices, such as, for example, ausculatory and prior oscillometric-based methods for monitoring blood pressure, are frequently ineffective with subjects such as neonates due to their relatively small size. In contrast, the sensor assemblies of the present invention are capable of accurately monitoring blood parameters in a relatively small biological entity by transmitting an optical signal through the limb or head of the biological entity. Indeed, the smaller the biological entity, the less tissue the optical signal has to traverse, resulting in a stronger signal that is received by the photodetector and subsequently analyzed to determine vital sign parameters such as, for example, blood pressure.
- In the foregoing discussion, the present invention has been drawn to a system and method for monitoring certain vital sign parameters of a neonate by directing an optical signal through the tissue of the neonate's limb or forehead. According to the embodiments discussed up until now, this is accomplished through the use of a cuff-based or patch-based structure that wraps around a limb or is position on a head, or, alternatively, into which a limb is inserted, the cuff and patch structure thereby retaining a light source and photodetector in proximity to the limb and head. However, it is envisioned that the present invention can be implemented in numerous other configurations that would be as equally effective in providing near-continuous monitoring of certain blood parameters of a neonate. For example, according to one additional embodiment of the invention, no such type of cuff structure is utilized. Instead, the light source and photodetector are selectively retained in proximity to the limb through the use of some form of clip or clamping structure that does not encircle the entire limb or, alternatively, through the use of a removable adhesive.
- The present invention has been particularly shown and described with reference to the foregoing embodiments, which are merely illustrative of the best modes for carrying out the invention. It should be understood by those skilled in the art that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention without departing from the spirit and scope of the invention as defined in the following claims. It is intended that the following claims define the scope of the invention and that the method and apparatus within the scope of these claims and their equivalents be covered thereby. This description of the invention should be understood to include all novel and non-obvious combinations of elements described herein, and claims may be presented in this or a later application to any novel and non-obvious combination of these elements. Moreover, the foregoing embodiments are illustrative, and no single feature or element is essential to all possible combinations that may be claimed in this or a later application.
Claims (16)
1-5. (canceled)
6. An oximetry monitoring system for monitoring a subject's tissue, comprising:
an adhesive forehead sensor comprising a light source and a photodetector in a side-by-side position, the light source emitting light at first and second wavelengths, and the photodetector providing an electrical signal in response to exposure to the light after reflectance by the monitored tissue;
a control system in communication with the photodetector, and equipped to sample the electrical signal and calculate an area under the curve metric responsive to a blood oxygen status of the monitored tissue; and
a display operated by the control system to provide an indication of the blood oxygen status.
7. The system of claim 6 , wherein the light source and the photodetector are carried by a flexible support.
8. The system of claim 7 , wherein the flexible support comprises an adhesive patch.
9. The system of claim 6 , further comprising an alarm triggered by the control system based on the blood oxygen status.
10. The system of claim 9 , wherein the blood oxygen status comprises a measure of oxygen saturation in the monitored tissue.
11. The system of claim 6 , wherein the blood oxygen status comprises a measure of tissue perfusion in the monitored tissue.
12. The system of claim 6 , wherein the control system comprises an analog to digital converter for sampling the electrical signal, and a processor programmed to calculate the area under the curve metric.
13. The system of claim 12 , wherein the processor is further programmed to calculate a tissue perfusion index based on the blood oxygen status over time.
14. The system of claim 6 , further comprising a database of reference characteristics, and wherein the control system is further programmed to compare the pulse waveform signal to the reference characteristics.
15. An oximetry system, comprising:
a sensor input receiving first and second electrical signals representative of light emitted by first and second emitters, reflected by a subject's tissue, and detected at first and second detectors;
a control system programmed to:
receive the first and second electrical signals and develop a pulse waveform signal representative of a blood parameter;
determine a value of the blood parameter based on the pulse waveform signal;
produce an area under the curve metric based on a pulse of the pulse waveform signal; and
determine a tissue perfusion index based on the area under the curve metric;
a display in communication with the control system; and
an alarm triggered by the control system based on a status of the pulse waveform signal.
16. The system of claim 15 , further comprising a database of reference characteristics, and wherein the control system is further programmed to compare the pulse waveform signal to the reference characteristics.
17. The system of claim 15 , further comprising an adhesive forehead sensor in communication with the sensor input, the adhesive forehead sensor comprising a light source and a photodetector in a side-by-side position, the light source emitting light at first and second wavelengths, and the photodetector providing the first and second electrical signals to the sensor input.
18. A method for monitoring vital sign parameters of a subject, comprising:
emitting light from first and second light emitters into a subject's forehead;
detecting the emitted light after reflectance by the subject's forehead, at first and second photodetectors;
generating first and second electrical signals representative of the detected light;
developing a pulse waveform signal based on the electrical signals;
analyzing the pulse waveform signal to produce an area under the curve metric;
monitoring the pulse waveform signal over time; and
displaying the pulse waveform signal.
19. The method of claim 18 , further comprising determining an oxygen saturation of the subject's tissue based on the first and second electrical signals.
20. The method of claim 18 , further comprising triggering an alarm based on a status of the pulse waveform signal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/649,908 US20170311824A1 (en) | 2004-10-05 | 2017-07-14 | Non-invasively monitoring blood parameters |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/958,458 US7341560B2 (en) | 2004-10-05 | 2004-10-05 | Apparatuses and methods for non-invasively monitoring blood parameters |
US12/025,564 US9380951B2 (en) | 2004-10-05 | 2008-02-04 | Non-invasively monitoring blood parameters |
US12/248,683 US20090312613A1 (en) | 2004-10-05 | 2008-10-09 | Non-invasively monitoring blood parameters |
US15/649,908 US20170311824A1 (en) | 2004-10-05 | 2017-07-14 | Non-invasively monitoring blood parameters |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/248,683 Continuation US20090312613A1 (en) | 2004-10-05 | 2008-10-09 | Non-invasively monitoring blood parameters |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170311824A1 true US20170311824A1 (en) | 2017-11-02 |
Family
ID=36126449
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/958,458 Expired - Lifetime US7341560B2 (en) | 2004-10-05 | 2004-10-05 | Apparatuses and methods for non-invasively monitoring blood parameters |
US12/025,564 Active 2029-07-06 US9380951B2 (en) | 2004-10-05 | 2008-02-04 | Non-invasively monitoring blood parameters |
US12/248,683 Abandoned US20090312613A1 (en) | 2004-10-05 | 2008-10-09 | Non-invasively monitoring blood parameters |
US15/649,908 Abandoned US20170311824A1 (en) | 2004-10-05 | 2017-07-14 | Non-invasively monitoring blood parameters |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/958,458 Expired - Lifetime US7341560B2 (en) | 2004-10-05 | 2004-10-05 | Apparatuses and methods for non-invasively monitoring blood parameters |
US12/025,564 Active 2029-07-06 US9380951B2 (en) | 2004-10-05 | 2008-02-04 | Non-invasively monitoring blood parameters |
US12/248,683 Abandoned US20090312613A1 (en) | 2004-10-05 | 2008-10-09 | Non-invasively monitoring blood parameters |
Country Status (3)
Country | Link |
---|---|
US (4) | US7341560B2 (en) |
EP (1) | EP1848321A4 (en) |
WO (1) | WO2006041789A2 (en) |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60334007D1 (en) * | 2002-10-01 | 2010-10-14 | Nellcor Puritan Bennett Inc | Use of headband for voltage indication and system of oximeter and headband |
US7764982B2 (en) | 2005-03-01 | 2010-07-27 | Masimo Laboratories, Inc. | Multiple wavelength sensor emitters |
US7047056B2 (en) | 2003-06-25 | 2006-05-16 | Nellcor Puritan Bennett Incorporated | Hat-based oximeter sensor |
US7485094B2 (en) * | 2003-09-30 | 2009-02-03 | Smithmarks, Inc. | Methods of diagnosis using pulse volume measurement |
US8412297B2 (en) * | 2003-10-01 | 2013-04-02 | Covidien Lp | Forehead sensor placement |
JP5096310B2 (en) * | 2005-03-14 | 2012-12-12 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Method and apparatus for determining blood perfusion in a body part |
US9198608B2 (en) | 2005-04-28 | 2015-12-01 | Proteus Digital Health, Inc. | Communication system incorporated in a container |
US8802183B2 (en) | 2005-04-28 | 2014-08-12 | Proteus Digital Health, Inc. | Communication system with enhanced partial power source and method of manufacturing same |
DK1889198T3 (en) | 2005-04-28 | 2015-02-09 | Proteus Digital Health Inc | Pharma-informatics system |
US8912908B2 (en) | 2005-04-28 | 2014-12-16 | Proteus Digital Health, Inc. | Communication system with remote activation |
US8730031B2 (en) | 2005-04-28 | 2014-05-20 | Proteus Digital Health, Inc. | Communication system using an implantable device |
US8836513B2 (en) | 2006-04-28 | 2014-09-16 | Proteus Digital Health, Inc. | Communication system incorporated in an ingestible product |
EP1920418A4 (en) | 2005-09-01 | 2010-12-29 | Proteus Biomedical Inc | Implantable zero-wire communications system |
US7904130B2 (en) | 2005-09-29 | 2011-03-08 | Nellcor Puritan Bennett Llc | Medical sensor and technique for using the same |
US7869850B2 (en) * | 2005-09-29 | 2011-01-11 | Nellcor Puritan Bennett Llc | Medical sensor for reducing motion artifacts and technique for using the same |
US7881762B2 (en) | 2005-09-30 | 2011-02-01 | Nellcor Puritan Bennett Llc | Clip-style medical sensor and technique for using the same |
US8005523B2 (en) * | 2005-09-30 | 2011-08-23 | Conmed Corporation | Signal processing for pulse oximetry |
US20070083094A1 (en) * | 2005-10-11 | 2007-04-12 | Colburn Joel C | Medical sensor and technique for using the same |
US20070106134A1 (en) | 2005-11-10 | 2007-05-10 | O'neil Michael P | Medical sensor and technique for using the same |
US8073518B2 (en) | 2006-05-02 | 2011-12-06 | Nellcor Puritan Bennett Llc | Clip-style medical sensor and technique for using the same |
KR101568660B1 (en) | 2006-05-02 | 2015-11-12 | 프로테우스 디지털 헬스, 인코포레이티드 | Patient On-Demand Therapy |
US8145288B2 (en) | 2006-08-22 | 2012-03-27 | Nellcor Puritan Bennett Llc | Medical sensor for reducing signal artifacts and technique for using the same |
US8219170B2 (en) | 2006-09-20 | 2012-07-10 | Nellcor Puritan Bennett Llc | System and method for practicing spectrophotometry using light emitting nanostructure devices |
US8396527B2 (en) * | 2006-09-22 | 2013-03-12 | Covidien Lp | Medical sensor for reducing signal artifacts and technique for using the same |
US8175671B2 (en) | 2006-09-22 | 2012-05-08 | Nellcor Puritan Bennett Llc | Medical sensor for reducing signal artifacts and technique for using the same |
US8190225B2 (en) | 2006-09-22 | 2012-05-29 | Nellcor Puritan Bennett Llc | Medical sensor for reducing signal artifacts and technique for using the same |
US8431088B2 (en) * | 2006-09-25 | 2013-04-30 | Covidien Lp | Carbon dioxide detector having borosilicate substrate |
US8420405B2 (en) * | 2006-09-25 | 2013-04-16 | Covidien Lp | Carbon dioxide detector having borosilicate substrate |
US8431087B2 (en) * | 2006-09-25 | 2013-04-30 | Covidien Lp | Carbon dioxide detector having borosilicate substrate |
US8449834B2 (en) * | 2006-09-25 | 2013-05-28 | Covidien Lp | Carbon dioxide detector having borosilicate substrate |
US8696593B2 (en) * | 2006-09-27 | 2014-04-15 | Covidien Lp | Method and system for monitoring intracranial pressure |
WO2008042559A2 (en) * | 2006-09-29 | 2008-04-10 | Koninklijke Philips Electronics N. V. | Method and apparatus for hands-free ultrasound |
JP4552919B2 (en) * | 2006-10-05 | 2010-09-29 | オムロンヘルスケア株式会社 | Sphygmomanometer cuff and sphygmomanometer |
US8054140B2 (en) | 2006-10-17 | 2011-11-08 | Proteus Biomedical, Inc. | Low voltage oscillator for medical devices |
JP4839179B2 (en) * | 2006-10-18 | 2011-12-21 | 敏明 中島 | Treatment system, treatment apparatus, and control method |
SG175681A1 (en) | 2006-10-25 | 2011-11-28 | Proteus Biomedical Inc | Controlled activation ingestible identifier |
US8718193B2 (en) | 2006-11-20 | 2014-05-06 | Proteus Digital Health, Inc. | Active signal processing personal health signal receivers |
US8858432B2 (en) | 2007-02-01 | 2014-10-14 | Proteus Digital Health, Inc. | Ingestible event marker systems |
MY154556A (en) | 2007-02-14 | 2015-06-30 | Proteus Digital Health Inc | In-body power source having high surface area electrode |
US20080221399A1 (en) * | 2007-03-05 | 2008-09-11 | Triage Wireless, Inc. | Monitor for measuring vital signs and rendering video images |
US9270025B2 (en) | 2007-03-09 | 2016-02-23 | Proteus Digital Health, Inc. | In-body device having deployable antenna |
EP2124725A1 (en) | 2007-03-09 | 2009-12-02 | Proteus Biomedical, Inc. | In-body device having a multi-directional transmitter |
US8540632B2 (en) | 2007-05-24 | 2013-09-24 | Proteus Digital Health, Inc. | Low profile antenna for in body device |
US8591430B2 (en) | 2007-09-14 | 2013-11-26 | Corventis, Inc. | Adherent device for respiratory monitoring |
WO2009036306A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Adherent cardiac monitor with advanced sensing capabilities |
WO2009036348A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Medical device automatic start-up upon contact to patient tissue |
US20090076345A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Adherent Device with Multiple Physiological Sensors |
WO2009036329A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Multi-sensor patient monitor to detect impending cardiac decompensation |
WO2009036333A1 (en) | 2007-09-14 | 2009-03-19 | Corventis, Inc. | Dynamic pairing of patients to data collection gateways |
US8684925B2 (en) | 2007-09-14 | 2014-04-01 | Corventis, Inc. | Injectable device for physiological monitoring |
US8961412B2 (en) | 2007-09-25 | 2015-02-24 | Proteus Digital Health, Inc. | In-body device with virtual dipole signal amplification |
US8577434B2 (en) * | 2007-12-27 | 2013-11-05 | Covidien Lp | Coaxial LED light sources |
US20090171226A1 (en) * | 2007-12-31 | 2009-07-02 | Nellcor Puritan Bennett Llc | System and method for evaluating variation in the timing of physiological events |
JP5045476B2 (en) * | 2008-02-08 | 2012-10-10 | オムロンヘルスケア株式会社 | Detection unit for blood pressure information measuring device and blood pressure information measuring device |
EP3827811A1 (en) | 2008-03-05 | 2021-06-02 | Otsuka Pharmaceutical Co., Ltd. | Multi-mode communication ingestible event markers and systems |
EP2257216B1 (en) | 2008-03-12 | 2021-04-28 | Medtronic Monitoring, Inc. | Heart failure decompensation prediction based on cardiac rhythm |
EP2306892A1 (en) * | 2008-04-15 | 2011-04-13 | Nonin Medical, Inc | Non-invasive optical sensor |
WO2009146214A1 (en) | 2008-04-18 | 2009-12-03 | Corventis, Inc. | Method and apparatus to measure bioelectric impedance of patient tissue |
WO2009144723A1 (en) * | 2008-05-28 | 2009-12-03 | Ofer Hornick | Method and apparatus for co2 evaluation |
US20090324033A1 (en) * | 2008-06-30 | 2009-12-31 | Nellcor Puritan Bennett Ireland | Signal Processing Systems and Methods for Determining Slope Using an Origin Point |
US8077297B2 (en) * | 2008-06-30 | 2011-12-13 | Nellcor Puritan Bennett Ireland | Methods and systems for discriminating bands in scalograms |
US8295567B2 (en) | 2008-06-30 | 2012-10-23 | Nellcor Puritan Bennett Ireland | Systems and methods for ridge selection in scalograms of signals |
US8827917B2 (en) * | 2008-06-30 | 2014-09-09 | Nelleor Puritan Bennett Ireland | Systems and methods for artifact detection in signals |
US20100004518A1 (en) | 2008-07-03 | 2010-01-07 | Masimo Laboratories, Inc. | Heat sink for noninvasive medical sensor |
ES2696984T3 (en) | 2008-07-08 | 2019-01-21 | Proteus Digital Health Inc | Ingestion event marker data infrastructure |
US8630691B2 (en) | 2008-08-04 | 2014-01-14 | Cercacor Laboratories, Inc. | Multi-stream sensor front ends for noninvasive measurement of blood constituents |
EP2313003B1 (en) | 2008-08-13 | 2016-08-03 | Proteus Digital Health, Inc. | Ingestible circuitry |
US8364220B2 (en) | 2008-09-25 | 2013-01-29 | Covidien Lp | Medical sensor and technique for using the same |
US8257274B2 (en) | 2008-09-25 | 2012-09-04 | Nellcor Puritan Bennett Llc | Medical sensor and technique for using the same |
US20100081892A1 (en) * | 2008-09-30 | 2010-04-01 | NelIcor Puritan Bennett Ireland | Systems and Methods for Combined Pulse Oximetry and Blood Pressure Measurement |
US8036748B2 (en) | 2008-11-13 | 2011-10-11 | Proteus Biomedical, Inc. | Ingestible therapy activator system and method |
AU2009324536A1 (en) | 2008-12-11 | 2011-07-14 | Proteus Digital Health, Inc. | Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same |
US9439566B2 (en) | 2008-12-15 | 2016-09-13 | Proteus Digital Health, Inc. | Re-wearable wireless device |
TWI503101B (en) | 2008-12-15 | 2015-10-11 | Proteus Digital Health Inc | Body-associated receiver and method |
US9659423B2 (en) | 2008-12-15 | 2017-05-23 | Proteus Digital Health, Inc. | Personal authentication apparatus system and method |
JP5785097B2 (en) | 2009-01-06 | 2015-09-24 | プロテウス デジタル ヘルス, インコーポレイテッド | Pharmaceutical dosage delivery system |
US9883819B2 (en) | 2009-01-06 | 2018-02-06 | Proteus Digital Health, Inc. | Ingestion-related biofeedback and personalized medical therapy method and system |
US11678808B2 (en) | 2009-03-13 | 2023-06-20 | Bluedop Medical, Ltd. | Haemodynamic data estimation apparatus and method of use |
GB2480965B (en) | 2009-03-25 | 2014-10-08 | Proteus Digital Health Inc | Probablistic pharmacokinetic and pharmacodynamic modeling |
US8515515B2 (en) | 2009-03-25 | 2013-08-20 | Covidien Lp | Medical sensor with compressible light barrier and technique for using the same |
US8781548B2 (en) | 2009-03-31 | 2014-07-15 | Covidien Lp | Medical sensor with flexible components and technique for using the same |
WO2010113522A1 (en) * | 2009-04-03 | 2010-10-07 | パナソニック株式会社 | Measurement device, and control method for measurement device |
SG10201810784SA (en) | 2009-04-28 | 2018-12-28 | Proteus Digital Health Inc | Highly Reliable Ingestible Event Markers And Methods For Using The Same |
EP2432458A4 (en) | 2009-05-12 | 2014-02-12 | Proteus Digital Health Inc | Ingestible event markers comprising an ingestible component |
KR101640498B1 (en) * | 2009-05-22 | 2016-07-19 | 삼성전자주식회사 | Blood pressure estimating apparatus and method by using variable characteristic ratio |
WO2011022732A2 (en) | 2009-08-21 | 2011-02-24 | Proteus Biomedical, Inc. | Apparatus and method for measuring biochemical parameters |
WO2011050283A2 (en) | 2009-10-22 | 2011-04-28 | Corventis, Inc. | Remote detection and monitoring of functional chronotropic incompetence |
TWI517050B (en) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | System for supply chain management |
US9492095B2 (en) | 2009-12-02 | 2016-11-15 | Neetour Medical Ltd. | Hemodynamics-based monitoring and evaluation of a respiratory condition |
UA109424C2 (en) | 2009-12-02 | 2015-08-25 | PHARMACEUTICAL PRODUCT, PHARMACEUTICAL TABLE WITH ELECTRONIC MARKER AND METHOD OF MANUFACTURING PHARMACEUTICAL TABLETS | |
US9451897B2 (en) | 2009-12-14 | 2016-09-27 | Medtronic Monitoring, Inc. | Body adherent patch with electronics for physiologic monitoring |
US8688185B2 (en) * | 2009-12-18 | 2014-04-01 | Envitec-Wismar Gmbh | Device for measuring blood, tissue, and skin parameters |
MX2012008922A (en) | 2010-02-01 | 2012-10-05 | Proteus Digital Health Inc | Data gathering system. |
US8965498B2 (en) | 2010-04-05 | 2015-02-24 | Corventis, Inc. | Method and apparatus for personalized physiologic parameters |
SG184494A1 (en) | 2010-04-07 | 2012-11-29 | Proteus Biomedical Inc | Miniature ingestible device |
TWI557672B (en) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | Computer system and computer-implemented method to track medication from manufacturer to a patient, apparatus and method for confirming delivery of medication to a patient, patient interface device |
WO2011159972A2 (en) | 2010-06-17 | 2011-12-22 | Welch Allyn, Inc. | Detection of noise during heart beat variation evaluation |
US12198790B1 (en) | 2010-10-07 | 2025-01-14 | Masimo Corporation | Physiological monitor sensor systems and methods |
GB201018413D0 (en) | 2010-11-01 | 2010-12-15 | Univ Cardiff | In-vivo monitoring with microwaves |
JP2014504902A (en) | 2010-11-22 | 2014-02-27 | プロテウス デジタル ヘルス, インコーポレイテッド | Ingestible device with medicinal product |
CN102551887A (en) * | 2010-12-09 | 2012-07-11 | 苏州生物医学工程技术研究所 | Graphic intelligent monitoring system for common diseases of neonates |
US9839362B2 (en) | 2010-12-23 | 2017-12-12 | Draeger Medical Systems, Inc. | Device and method for combined continuous non-invasive measurement of blood pressure and pulse oximetry (SpO2) |
US8721557B2 (en) | 2011-02-18 | 2014-05-13 | Covidien Lp | Pattern of cuff inflation and deflation for non-invasive blood pressure measurement |
US9072433B2 (en) | 2011-02-18 | 2015-07-07 | Covidien Lp | Method and apparatus for noninvasive blood pressure measurement using pulse oximetry |
EP2683291B1 (en) | 2011-03-11 | 2019-07-31 | Proteus Digital Health, Inc. | Wearable personal body associated device with various physical configurations |
US8747328B2 (en) * | 2011-04-29 | 2014-06-10 | Raytheon Bbn Technologies Corp. | Continuous blood pressure monitoring |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
MX340001B (en) | 2011-07-21 | 2016-06-20 | Proteus Digital Health Inc | DEVICE, SYSTEM AND METHOD OF MOBILE COMMUNICATION. |
US9408573B2 (en) * | 2011-08-11 | 2016-08-09 | Sotera Wireless, Inc. | Patient interface for reusable optical sensor |
US8852095B2 (en) * | 2011-10-27 | 2014-10-07 | Covidien Lp | Headband for use with medical sensor |
US9235683B2 (en) | 2011-11-09 | 2016-01-12 | Proteus Digital Health, Inc. | Apparatus, system, and method for managing adherence to a regimen |
KR20150038038A (en) | 2012-07-23 | 2015-04-08 | 프로테우스 디지털 헬스, 인코포레이티드 | Techniques for manufacturing ingestible event markers comprising an ingestible component |
US20140073878A1 (en) * | 2012-09-11 | 2014-03-13 | Nellcor Puritan Bennett Llc | Methods and systems for determining physiological information using autocorrelation based on a modified signal |
EP2906104B1 (en) * | 2012-10-09 | 2016-06-08 | Koninklijke Philips N.V. | System and method for breathing rate measurements |
JP5869736B2 (en) | 2012-10-18 | 2016-02-24 | プロテウス デジタル ヘルス, インコーポレイテッド | Apparatus, system, and method for adaptively optimizing power dissipation and broadcast power in a power supply for a communication device |
JP2016508529A (en) | 2013-01-29 | 2016-03-22 | プロテウス デジタル ヘルス, インコーポレイテッド | Highly expandable polymer film and composition containing the same |
US9662051B2 (en) * | 2013-03-08 | 2017-05-30 | D.E. Hokanson, Inc. | Automated assessment of peripheral vascular condition |
WO2014151929A1 (en) | 2013-03-15 | 2014-09-25 | Proteus Digital Health, Inc. | Personal authentication apparatus system and method |
US10175376B2 (en) | 2013-03-15 | 2019-01-08 | Proteus Digital Health, Inc. | Metal detector apparatus, system, and method |
JP6511439B2 (en) | 2013-06-04 | 2019-05-15 | プロテウス デジタル ヘルス, インコーポレイテッド | Systems, devices, and methods for data collection and outcome assessment |
US9796576B2 (en) | 2013-08-30 | 2017-10-24 | Proteus Digital Health, Inc. | Container with electronically controlled interlock |
KR101656483B1 (en) | 2013-09-20 | 2016-09-09 | 프로테우스 디지털 헬스, 인코포레이티드 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
US9577864B2 (en) | 2013-09-24 | 2017-02-21 | Proteus Digital Health, Inc. | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
CN103793593B (en) * | 2013-11-15 | 2018-02-13 | 吴一兵 | One kind obtains brain states objective quantitative and refers to calibration method |
US10342488B2 (en) * | 2014-02-24 | 2019-07-09 | The Trustees Of The University Of Pennsylvania | Probes and pressure modulation algorithms for reducing extratissue contamination in hemodynamic measurement |
US10758130B2 (en) * | 2014-03-31 | 2020-09-01 | Welch Allyn, Inc. | Single site vitals |
US9844341B2 (en) | 2014-08-14 | 2017-12-19 | Zoll Medical Corporation | Patient interface for reusable optical sensor |
US11051543B2 (en) | 2015-07-21 | 2021-07-06 | Otsuka Pharmaceutical Co. Ltd. | Alginate on adhesive bilayer laminate film |
CN109069075A (en) * | 2015-08-05 | 2018-12-21 | X卡迪欧柯普株式会社 | concave optical sensor |
US20170049404A1 (en) * | 2015-08-19 | 2017-02-23 | Amiigo, Inc. | Wearable LED Sensor Device Configured to Identify a Wearer's Pulse |
US11660063B2 (en) | 2015-11-18 | 2023-05-30 | Bluedop Medical, Ltd. | System for determining peripheral artery disease and method of use |
US11350837B2 (en) | 2016-03-30 | 2022-06-07 | Elfi-Tech Ltd. | Method and apparatus for optically measuring blood pressure |
US11134901B2 (en) | 2016-03-30 | 2021-10-05 | Elfi-Tech Ltd. | Method and apparatus for optically measuring blood pressure |
RU2711058C1 (en) | 2016-07-22 | 2020-01-14 | Протеус Диджитал Хелс, Инк. | Electromagnetic probing and detection of swallowed event markers |
EP3525674B1 (en) | 2016-10-12 | 2021-12-08 | Elfi-Tech Ltd. | Method and apparatus for optically measuring blood pressure |
IL265827B2 (en) | 2016-10-26 | 2023-03-01 | Proteus Digital Health Inc | Methods for manufacturing capsules with ingestible event markers |
US20190104991A1 (en) * | 2017-10-11 | 2019-04-11 | Edwards Lifesciences Corporation | Self closing finger cuff |
JP7534584B2 (en) | 2018-01-02 | 2024-08-15 | ブルードップ メディカル リミテッド | System for determining peripheral arterial disease - Patents.com |
US12194620B2 (en) | 2018-10-15 | 2025-01-14 | Oliver Crisipin Robotics Limited | Selectively flexible extension tool |
US11707819B2 (en) | 2018-10-15 | 2023-07-25 | General Electric Company | Selectively flexible extension tool |
US11702955B2 (en) | 2019-01-14 | 2023-07-18 | General Electric Company | Component repair system and method |
US20210076958A1 (en) | 2019-09-12 | 2021-03-18 | Vivonics, Inc. | System and method for non-invasively measuring blood volume oscillations inside the cranium of a human subject and determining intracranial pressure |
KR20220129033A (en) | 2020-01-13 | 2022-09-22 | 마시모 코오퍼레이션 | Wearable device with physiological parameter monitoring function |
US11692650B2 (en) | 2020-01-23 | 2023-07-04 | General Electric Company | Selectively flexible extension tool |
US11752622B2 (en) | 2020-01-23 | 2023-09-12 | General Electric Company | Extension tool having a plurality of links |
US11613003B2 (en) | 2020-01-24 | 2023-03-28 | General Electric Company | Line assembly for an extension tool having a plurality of links |
US11371437B2 (en) | 2020-03-10 | 2022-06-28 | Oliver Crispin Robotics Limited | Insertion tool |
US12091981B2 (en) | 2020-06-11 | 2024-09-17 | General Electric Company | Insertion tool and method |
US20230301529A1 (en) * | 2020-08-21 | 2023-09-28 | Buluedop Medical, Ltd | Continuous blood pressure monitoring |
US11654547B2 (en) | 2021-03-31 | 2023-05-23 | General Electric Company | Extension tool |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3796213A (en) * | 1970-09-18 | 1974-03-12 | F Stephens | Perfusion monitor |
US20020035315A1 (en) * | 1999-01-07 | 2002-03-21 | Ali Ammar Al | Pulse oximetry data confidence indicator |
US20020095077A1 (en) * | 2000-08-31 | 2002-07-18 | David Swedlow | Oximeter sensor with digital memory encoding patient data |
US20030018241A1 (en) * | 2001-07-19 | 2003-01-23 | Nellcor Puritan Bennett Inc. | Nuisance alarm reductions in a physiological monitor |
US20030036690A1 (en) * | 2001-06-20 | 2003-02-20 | Geddes Leslie A. | Body-member-illuminating pressure cuff for use in optical noninvasive measurement of blood parameters |
US20030109775A1 (en) * | 2001-10-12 | 2003-06-12 | Nellcor Puritan Bennett Inc. | Stacked adhesive optical sensor |
US20040044276A1 (en) * | 2002-08-27 | 2004-03-04 | Donald Arnold | Method and appratus for measuring pulsus paradoxus |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5020540A (en) * | 1987-10-09 | 1991-06-04 | Biometrak Corporation | Cardiac biopotential analysis system and method |
US4949725A (en) * | 1988-07-01 | 1990-08-21 | Bio-Logic Systems Corporation | Apparatus and method for displaying electrical activity generated within a living body |
US5111817A (en) * | 1988-12-29 | 1992-05-12 | Medical Physics, Inc. | Noninvasive system and method for enhanced arterial oxygen saturation determination and arterial blood pressure monitoring |
CA2089732A1 (en) * | 1990-08-31 | 1992-03-01 | Phillip D. Baker | Method and apparatus for determining blood pressure |
US5379774A (en) * | 1990-10-23 | 1995-01-10 | Sankyo Company Limited | Measurement of arterial elasticity and the frequency characteristic of the compliance of an artery |
US5183051A (en) * | 1991-01-14 | 1993-02-02 | Jonathan Kraidin | Means and apparatus for continuously determining cardiac output in a subject |
US5181518A (en) * | 1991-02-04 | 1993-01-26 | Mcdonagh Paul F | Method of evaluating cardioprotective agents |
US5148812A (en) * | 1991-02-20 | 1992-09-22 | Georgetown University | Non-invasive dynamic tracking of cardiac vulnerability by analysis of t-wave alternans |
US5247931A (en) * | 1991-09-16 | 1993-09-28 | Mine Safety Appliances Company | Diagnostic sensor clasp utilizing a slot, pivot and spring hinge mechanism |
JP2979933B2 (en) * | 1993-08-03 | 1999-11-22 | セイコーエプソン株式会社 | Pulse wave analyzer |
US5533511A (en) * | 1994-01-05 | 1996-07-09 | Vital Insite, Incorporated | Apparatus and method for noninvasive blood pressure measurement |
US5676139A (en) * | 1994-12-14 | 1997-10-14 | Ohmeda Inc. | Spring clip probe housing |
US5995857A (en) * | 1996-07-01 | 1999-11-30 | Toomim; I. Hershel | Biofeedback of human central nervous system activity using radiation detection |
US5836887A (en) * | 1996-09-19 | 1998-11-17 | Colin Corporation | Physical information monitor system having means for determining reference range for abnormality determination, based on moving average of previously obtained values |
US6018673A (en) * | 1996-10-10 | 2000-01-25 | Nellcor Puritan Bennett Incorporated | Motion compatible sensor for non-invasive optical blood analysis |
US5868679A (en) * | 1996-11-14 | 1999-02-09 | Colin Corporation | Blood-pressure monitor apparatus |
DE59812090D1 (en) * | 1997-08-09 | 2004-11-11 | Roche Diagnostics Gmbh | ANALYSIS DEVICE FOR IN VIVO ANALYSIS IN THE BODY OF A PATIENT |
US6050951A (en) * | 1997-11-10 | 2000-04-18 | Critikon Company, L.L.C. | NIBP trigger in response to detected heart rate variability |
EP1082050B1 (en) * | 1998-06-03 | 2011-08-24 | Masimo Corporation | Stereo pulse oximeter |
EP0904727B1 (en) * | 1998-06-05 | 2000-10-18 | Hewlett-Packard Company | Pulse rate and heart rate coincidence detection for pulse oximetry |
JP2000126142A (en) * | 1998-10-29 | 2000-05-09 | Nippon Colin Co Ltd | Non-regard blood continuous blood pressure estimating device |
US6298267B1 (en) * | 1999-04-30 | 2001-10-02 | Intermedics Inc. | Method and apparatus for treatment of cardiac electromechanical dissociation |
US6287252B1 (en) * | 1999-06-30 | 2001-09-11 | Monitrak | Patient monitor |
US6470893B1 (en) * | 2000-05-15 | 2002-10-29 | Peter V. Boesen | Wireless biopotential sensing device and method with capability of short-range radio frequency transmission and reception |
US6648820B1 (en) * | 1999-10-27 | 2003-11-18 | Home-Medicine (Usa), Inc. | Medical condition sensing system |
US6277078B1 (en) * | 1999-11-19 | 2001-08-21 | Remon Medical Technologies, Ltd. | System and method for monitoring a parameter associated with the performance of a heart |
US6591123B2 (en) * | 2000-08-31 | 2003-07-08 | Mallinckrodt Inc. | Oximeter sensor with digital memory recording sensor data |
US7139404B2 (en) * | 2001-08-10 | 2006-11-21 | Hear-Wear Technologies, Llc | BTE/CIC auditory device and modular connector system therefor |
IL145445A (en) * | 2001-09-13 | 2006-12-31 | Conmed Corp | Signal processing method and device for signal-to-noise improvement |
US6701170B2 (en) * | 2001-11-02 | 2004-03-02 | Nellcor Puritan Bennett Incorporated | Blind source separation of pulse oximetry signals |
US6776764B2 (en) * | 2002-03-01 | 2004-08-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of aortic pulse pressure and flow in bedside hemodynamic management |
US6850788B2 (en) * | 2002-03-25 | 2005-02-01 | Masimo Corporation | Physiological measurement communications adapter |
JP2003310579A (en) * | 2002-04-24 | 2003-11-05 | Nippon Colin Co Ltd | Organism monitoring apparatus |
AUPS214502A0 (en) * | 2002-05-06 | 2002-06-06 | Uscom Pty Ltd | Blood flow oxygen measurement |
JP4465271B2 (en) * | 2002-07-26 | 2010-05-19 | シーエーエス・メディカル・システムズ・インコーポレイテッド | Apparatus for noninvasively determining blood oxygen saturation in a target tissue |
DE60334007D1 (en) * | 2002-10-01 | 2010-10-14 | Nellcor Puritan Bennett Inc | Use of headband for voltage indication and system of oximeter and headband |
AU2002952144A0 (en) * | 2002-10-17 | 2002-10-31 | Perfusion Diagnostics Pty Ltd | Method and apparatus for measuring tissue perfusion |
JP4528766B2 (en) * | 2003-01-24 | 2010-08-18 | プロテウス バイオメディカル インコーポレイテッド | System for remote hemodynamic monitoring |
US7330750B2 (en) * | 2003-04-25 | 2008-02-12 | Instrumentarium Corp. | Estimation of cardiac death risk |
US20040220640A1 (en) * | 2003-04-29 | 2004-11-04 | Medtronic, Inc. | Method and apparatus for determining myocardial electrical resitution and controlling extra systolic stimulation |
US20040249299A1 (en) * | 2003-06-06 | 2004-12-09 | Cobb Jeffrey Lane | Methods and systems for analysis of physiological signals |
US20040249302A1 (en) * | 2003-06-09 | 2004-12-09 | Cyberkinetics, Inc. | Methods and systems for processing of brain signals |
US7381187B2 (en) * | 2003-09-12 | 2008-06-03 | Textronics, Inc. | Blood pressure monitoring system and method of having an extended optical range |
-
2004
- 2004-10-05 US US10/958,458 patent/US7341560B2/en not_active Expired - Lifetime
-
2005
- 2005-10-04 EP EP05802897A patent/EP1848321A4/en not_active Withdrawn
- 2005-10-04 WO PCT/US2005/035520 patent/WO2006041789A2/en active Search and Examination
-
2008
- 2008-02-04 US US12/025,564 patent/US9380951B2/en active Active
- 2008-10-09 US US12/248,683 patent/US20090312613A1/en not_active Abandoned
-
2017
- 2017-07-14 US US15/649,908 patent/US20170311824A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3796213A (en) * | 1970-09-18 | 1974-03-12 | F Stephens | Perfusion monitor |
US20020035315A1 (en) * | 1999-01-07 | 2002-03-21 | Ali Ammar Al | Pulse oximetry data confidence indicator |
US20020095077A1 (en) * | 2000-08-31 | 2002-07-18 | David Swedlow | Oximeter sensor with digital memory encoding patient data |
US20030036690A1 (en) * | 2001-06-20 | 2003-02-20 | Geddes Leslie A. | Body-member-illuminating pressure cuff for use in optical noninvasive measurement of blood parameters |
US20030018241A1 (en) * | 2001-07-19 | 2003-01-23 | Nellcor Puritan Bennett Inc. | Nuisance alarm reductions in a physiological monitor |
US20030109775A1 (en) * | 2001-10-12 | 2003-06-12 | Nellcor Puritan Bennett Inc. | Stacked adhesive optical sensor |
US20040044276A1 (en) * | 2002-08-27 | 2004-03-04 | Donald Arnold | Method and appratus for measuring pulsus paradoxus |
Also Published As
Publication number | Publication date |
---|---|
EP1848321A2 (en) | 2007-10-31 |
WO2006041789A3 (en) | 2006-06-01 |
US20080132769A1 (en) | 2008-06-05 |
EP1848321A4 (en) | 2011-03-02 |
US20060074283A1 (en) | 2006-04-06 |
WO2006041789A2 (en) | 2006-04-20 |
US7341560B2 (en) | 2008-03-11 |
US20090312613A1 (en) | 2009-12-17 |
US9380951B2 (en) | 2016-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7341560B2 (en) | Apparatuses and methods for non-invasively monitoring blood parameters | |
US5111817A (en) | Noninvasive system and method for enhanced arterial oxygen saturation determination and arterial blood pressure monitoring | |
US6801798B2 (en) | Body-member-illuminating pressure cuff for use in optical noninvasive measurement of blood parameters | |
EP3270772B1 (en) | Method and apparatus for measuring blood pressure | |
US6553242B1 (en) | Physiological stress detector device and method | |
CA2492027C (en) | Body surface probe, apparatus and method for non-invasively detecting medical conditions | |
US20130060147A1 (en) | Occlusive non-inflatable blood pressure device | |
WO1991011137A1 (en) | Enhanced arterial oxygen saturation determination and arterial blood pressure monitoring | |
US9072433B2 (en) | Method and apparatus for noninvasive blood pressure measurement using pulse oximetry | |
JP2015502197A (en) | Optical sensor for use in vital sign monitoring | |
US20100081892A1 (en) | Systems and Methods for Combined Pulse Oximetry and Blood Pressure Measurement | |
US12036005B2 (en) | Apparatus and methods for measuring blood pressure and other vital signs via a finger | |
US20230293026A1 (en) | Photoplethysmography-based Blood Pressure Monitoring Device | |
KR20200129811A (en) | Blood Pressure Meter And Method For Measuring Blood Pressure Using The Same | |
US12268481B2 (en) | Photoplethysmography-based blood pressure monitoring device | |
JPH05503856A (en) | Enhanced arterial oxygen saturation determination method and arterial blood pressure monitoring method | |
US20230363653A1 (en) | Wearable vital signs monitoring device and method | |
WO2024238220A1 (en) | Photoplethysmography-based blood pressure monitoring device | |
JPH0221844A (en) | Hemandynamometer probe and blood pressure measuring device | |
AU2002318363A1 (en) | Body-member-illuminating pressure cuff for noninvasive optical measurement |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |